var title_f7_44_7872="Ear canal exostoses";
var content_f7_44_7872=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53371&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53371&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ear canal exostoses",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ear canal exostoses (outgrowths of bone into the external ear canal).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD, FAAP, FACS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_44_7872=[""].join("\n");
var outline_f7_44_7872=null;
var title_f7_44_7873="Mature fire ant colonies size";
var content_f7_44_7873=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F73265&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F73265&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Different sizes of worker ants found in mature fire ant colonies",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 286px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A wide spectrum of different sized ants are found in mature fire ant colonies, with the majority of workers being the smallest in size. A queen is shown on the right. Ten millimeters (mm) is approximately three-eighths of an inch.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Vinson SB, Sorensen AA. Imported fire ants: Life history and impact. Texas Department of Agriculture 1986. Copyright &copy; 1986 Texas Department of Agriculture.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_44_7873=[""].join("\n");
var outline_f7_44_7873=null;
var title_f7_44_7874="Normal cervix on ultrasound";
var content_f7_44_7874=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F72281&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F72281&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal cervix",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 334px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ultrasound of normal cervix with equal thickness of anterior and posterior cervical lips. X marks the internal cervical os; + marks the external cervical os; the echodense line connecting the two points is the endocervical canal.",
"    <div class=\"footnotes\">",
"     AF: amniotic fluid; VTX: fetal head.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey Johnson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_44_7874=[""].join("\n");
var outline_f7_44_7874=null;
var title_f7_44_7875="Bovine lipid extract surfactant: Drug information";
var content_f7_44_7875=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Bovine lipid extract surfactant: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F10434578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      BLES",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F10434581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Lung Surfactant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F10434663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Respiratory distress:",
"     </b>",
"     <i>",
"      Rescue treatment:",
"     </i>",
"     Intratracheal: Infants: Administer 5 mL/kg/dose (equals phospholipids 135 mg/kg/dose); may repeat if needed, to a maximum of 4 doses within the first 5 days of life.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F10434707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Suspension, intratracheal [bovine derived, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     BLES&reg;: Phospholipids 27 mg/mL  (3 mL, 4 mL, 5 mL)",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11236624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10434704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      For intratracheal administration only.",
"     </b>",
"     Suction infant prior to administration. Inspect solution to verify complete mixing of the suspension (may swirl gently, but",
"     <b>",
"      DO NOT SHAKE",
"     </b>",
"     ). Do not filter dose. After proper placement of ETT has been established, administer intratracheally by instillation through a #5-French feeding tube inserted into the infant's ETT.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Administer as a single bolus dose or administer dose in up to 3 aliquots as tolerated. Each dose or aliquot is instilled over 2-3 seconds followed by at least 30 seconds of manual ventilation. Avoid administering as a slow drip or in small aliquots as this may lead to poor distribution and uneven lung compliance.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Infant should be supine for the first aliquot, than turned to the left and right for subsequent aliquots. Allow 1-2 minute recovery periods after each aliquot; oxygen saturation should be ~95% before administration of next aliquot. Following administration of one full dose, withhold suctioning for 2 hours unless clinically necessary.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10434583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of neonatal respiratory distress syndrome (NRDS)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F10434649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Bradycardia (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Pulmonary function decreased (defined as decreased oxygen saturation or increased CO",
"     <sub>",
"      2",
"     </sub>",
"     ) (39%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Sepsis (28%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Hypotension (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Periventricular leukomalacia (8%), seizures (2%), hydrocephalus (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Pulmonary interstitial emphysema (9%), pneumothorax (8%), pulmonary hemorrhage (8%), endotracheal tube complications (6%), respiratory acidosis (4%), apnea (2%), pneumonia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening):  Acidosis, hypertension, hypoxia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10434645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Active pulmonary hemorrhage",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10434646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Mucous plugs: Marked impairment of ventilation during or shortly after dosing may indicate mucous plugs within the endotracheal tube (ETT); suctioning prior to administration may decrease chance of ETT obstruction. Replace ETT immediately if obstruction is not removed with suctioning.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Sepsis: Therapy may be associated with increased incidence of sepsis; monitor closely for signs/symptoms of sepsis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Transient adverse effects: Transient episodes of bradycardia and decreased oxygen saturation may occur. Discontinue dosing procedure and initiate measures to alleviate the condition; may reinstitute after the patient is stable.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Administration: For intratracheal administration only. Correct any acidosis, hypoglycemia, hypothermia, or hypotension prior to administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Monitoring: Rapidly affects oxygenation and lung compliance; hyperoxia may occur within minutes of administration. Assess and adjust ventilator and oxygen delivery as necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Trained personnel: Restrict use to a highly-supervised clinical setting with immediate availability of clinicians experienced in intubation and ventilatory management of premature infants.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F10434653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F17916778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bovine lipid extract surfactant is only indicated for use in premature infants.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10434706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Continuous ECG and transcutaneous O",
"     <sub>",
"      2",
"     </sub>",
"     saturation should be monitored during administration; after administration, frequent arterial blood gas sampling is necessary to prevent postdosing hyperoxia and hypocarbia; tidal volume after dosing",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10434657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Replaces deficient or ineffective endogenous lung surfactant in neonates with respiratory distress syndrome (RDS). Surfactant prevents the alveoli from collapsing during expiration by lowering surface tension between air and alveolar surfaces.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10434659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: 5-30 minutes",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Canadian Paediatric Society, &ldquo;Recommendations for Neonatal Surfactant Therapy,&rdquo;",
"      <i>",
"       Paediatr Child Health",
"      </i>",
"      , 2005, 10(2):109-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/44/7875/abstract-text/19668609/pubmed\" id=\"19668609\" target=\"_blank\">",
"        19668609",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lam BC, Ng YK, and Wong KY, &ldquo;Randomized Trial Comparing Two Natural Surfactants (Survanta vs. bLES) for Treatment of Neonatal Respiratory Distress Syndrome,&rdquo;",
"      <i>",
"       Pediatr Pulmonol",
"      </i>",
"      , 2005, 39(1):64-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/44/7875/abstract-text/15558604/pubmed\" id=\"15558604\" target=\"_blank\">",
"        15558604",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sinha S, Moya F, and Donn SM, &ldquo;Surfactant for Respiratory Distress Syndrome: Are There Important Clinical Differences Among Preparations,&rdquo;",
"      <i>",
"       Curr Opin Pediatr",
"      </i>",
"      , 2007, 19(2):150-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/44/7875/abstract-text/17496757/pubmed\" id=\"17496757\" target=\"_blank\">",
"        17496757",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sweet D, Bevilacqua G, Carnielli V, et al, &ldquo;European Consensus Guidelines on the Management of Neonatal Respiratory Distress Syndrome,&rdquo;",
"      <i>",
"       J Perinat Med",
"      </i>",
"      , 2007, 35(3):175-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/44/7875/abstract-text/17480144/pubmed\" id=\"17480144\" target=\"_blank\">",
"        17480144",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15583 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-3A8E13EC2C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_44_7875=[""].join("\n");
var outline_f7_44_7875=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10434578\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10434581\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10434663\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10434707\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11236624\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10434704\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10434583\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10434649\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10434645\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10434646\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298880\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10434653\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F17916778\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10434706\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10434657\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10434659\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/15583\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/15583|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_44_7876="Pilocarpine (systemic): Pediatric drug information";
var content_f7_44_7876=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pilocarpine (systemic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33652?source=see_link\">",
"    see \"Pilocarpine (systemic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?27/52/28484?source=see_link\">",
"    see \"Pilocarpine (systemic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9505050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Salagen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9505051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Salagen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10512734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Cholinergic Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10512765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33652?source=see_link\">",
"      see \"Pilocarpine (systemic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Xerostomia: Adults: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Following head and neck cancer: 5 mg 3 times/day, titration up to 10 mg 3 times/day may be considered for patients who have not responded adequately; not to exceed 10 mg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Sj&ouml;gren's syndrome: 5 mg 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     Adults: Oral: Patients with moderate impairment: 5 mg 2 times/day regardless of indication; avoid use in severe hepatic impairment",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9505264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 5 mg, 7.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Salagen&reg;: 5 mg, 7.5 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9505053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10512766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with or without food; avoid administration with high-fat meal",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10512747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic treatment of xerostomia caused by salivary gland hypofunction resulting from radiotherapy for cancer of the head and neck; and in Sj&ouml;gren's syndrome",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9505046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Salagen&reg; may be confused with selegiline",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F9505076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Edema, facial edema, flushing, hypertension, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, dizziness, fever, headache, pain, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, dyspepsia, constipation, flatulence, glossitis, increased salivation, nausea, stomatitis, taste perversion, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary frequency, urinary incontinence, vaginitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgias, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Abnormal vision, amblyopia, blurred vision, conjunctivitis lacrimation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dysphagia, epistaxis, increased cough, rhinitis, sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, diaphoresis, voice alteration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abnormal dreams, alopecia, angina pectoris, anorexia, anxiety, arrhythmia, body odor, bone disorder, cholelithiasis, colitis, confusion, dry eyes, dry mouth, ECG abnormality, myasthenia, photosensitivity reaction, nervousness, pancreatitis, paresthesia, salivary gland enlargement, sputum increased, taste loss, tongue disorder, urinary impairment, urinary urgency, yawning",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10512748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pilocarpine or any component; severe hepatic impairment",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10512750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with pre-existing CHF, asthma, peptic ulcer, urinary tract obstruction, Parkinson's disease",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10512749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduce dosage in hepatic impairment",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9505085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2A6 (weak), CYP2E1 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9505086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: May enhance the adverse/toxic effect of Cholinergic Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction. Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F10512753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     High-fat meals decrease the rate of oral absorption and maximum serum concentration; the time to reach maximum concentrations is also increased",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9505064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9887311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal studies.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10512767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Salivation (xerostomia treatment)",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F10512754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increased salivary flow",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: 20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maximum effect: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: 3-5 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10512764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life, elimination: 0.76-1.35 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Mild to moderate hepatic impairment: 2.1 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16041 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-704953041C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_44_7876=[""].join("\n");
var outline_f7_44_7876=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505050\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505051\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512734\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512765\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505264\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505053\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512766\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512747\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505046\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505076\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512748\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512750\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512749\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505085\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505086\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512753\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505064\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9887311\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512767\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512754\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512764\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16041\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16041|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4548?source=related_link\">",
"      Pilocarpine (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/3/18484?source=related_link\">",
"      Pilocarpine (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/40/25219?source=related_link\">",
"      Pilocarpine (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33652?source=related_link\">",
"      Pilocarpine (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?27/52/28484?source=related_link\">",
"      Pilocarpine (systemic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_44_7877="Guaifenesin, dextromethorphan, and phenylephrine: Patient drug information";
var content_f7_44_7877=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Guaifenesin, dextromethorphan, and phenylephrine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/16/44292?source=see_link\">",
"     see \"Guaifenesin, dextromethorphan, and phenylephrine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F1698817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Maxiphen DM [DSC];",
"     </li>",
"     <li>",
"      Maxiphen DMX;",
"     </li>",
"     <li>",
"      Mucinex&reg; Children&rsquo;s Multi-Symptom Cold [OTC];",
"     </li>",
"     <li>",
"      Robafen CF Cough &amp; Cold [OTC];",
"     </li>",
"     <li>",
"      Robitussin&reg; Children's Cough &amp; Cold CF [OTC];",
"     </li>",
"     <li>",
"      Robitussin&reg; Peak Cold Maximum Strength Multi-Symptom Cold [OTC];",
"     </li>",
"     <li>",
"      Robitussin&reg; Peak Cold Multi-Symptom Cold [OTC];",
"     </li>",
"     <li>",
"      SINUtuss&reg; DM [DSC];",
"     </li>",
"     <li>",
"      Tusso&trade;-DMR [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10021344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10021346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691980",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat nose stuffiness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691646",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop coughing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691653",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to thin mucous so it can be taken from the body by coughing.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10021345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702222",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to guaifenesin, dextromethorphan, phenylephrine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703530",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: A large prostate gland, heart disease, or very high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10021350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10021351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10021353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10021348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694356",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (syrup) if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10021349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10021354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10021355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11537 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.123.134.1-8BED796ECD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_44_7877=[""].join("\n");
var outline_f7_44_7877=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1698817\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021344\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021346\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021345\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021350\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021351\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021353\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021348\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021349\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021354\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021355\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/16/44292?source=related_link\">",
"      Guaifenesin, dextromethorphan, and phenylephrine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_44_7878="Baclofen: Pediatric drug information";
var content_f7_44_7878=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Baclofen: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?35/31/36342?source=see_link\">",
"    see \"Baclofen: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?40/48/41732?source=see_link\">",
"    see \"Baclofen: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F138898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Gablofen&reg;;",
"     </li>",
"     <li>",
"      Lioresal&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F138899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Baclofen&reg;;",
"     </li>",
"     <li>",
"      Ava-Baclofen;",
"     </li>",
"     <li>",
"      Dom-Baclofen;",
"     </li>",
"     <li>",
"      Lioresal&reg;;",
"     </li>",
"     <li>",
"      Lioresal&reg; D.S.;",
"     </li>",
"     <li>",
"      Lioresal&reg; Intrathecal;",
"     </li>",
"     <li>",
"      Med-Baclofen;",
"     </li>",
"     <li>",
"      Mylan-Baclofen;",
"     </li>",
"     <li>",
"      Novo-Baclofen;",
"     </li>",
"     <li>",
"      Nu-Baclo;",
"     </li>",
"     <li>",
"      PHL-Baclofen;",
"     </li>",
"     <li>",
"      PMS-Baclofen;",
"     </li>",
"     <li>",
"      ratio-Baclofen;",
"     </li>",
"     <li>",
"      Riva-Baclofen",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1056749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Skeletal Muscle Relaxant, Nonparalytic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1056743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/31/36342?source=see_link\">",
"      see \"Baclofen: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Dose-related side effects (eg, sedation) may be minimized by slow titration; lower initial doses than described below (2.5-5 mg",
"     <b>",
"      daily",
"     </b>",
"     ) may be used with subsequent titration to 8 hourly doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: Limited published data in children; the following is a compilation of small prospective studies (Albright, 1996; Milla, 1977; Scheinberg, 2006) and one large retrospective analysis of baclofen use in children (Lubsch, 2006):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &lt;2 years: 10-20 mg",
"     <b>",
"      daily",
"     </b>",
"     divided every 8 hours; titrate dose every 3 days in increments of 5-15 mg/day to a maximum of 40 mg",
"     <b>",
"      daily",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     2-7 years: 20-30 mg",
"     <b>",
"      daily",
"     </b>",
"     divided every 8 hours; titrate dose every 3 days in increments of 5-15 mg/day to a maximum of 60 mg",
"     <b>",
"      daily",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;8 years: 30-40 mg",
"     <b>",
"      daily",
"     </b>",
"     divided every 8 hours; titrate dosage as above to a maximum of 120 mg",
"     <b>",
"      daily",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Lubsch retrospective analysis noted that higher daily dosages of baclofen were needed as the time increased from injury onset, as age increased, and as the number of concomitant antispasticity medications increased.  Each of these variables may represent drug tolerance or progressive spasticity.  In this review, doses as high as 200 mg",
"     <b>",
"      daily",
"     </b>",
"     were used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 5 mg 3 times/day, may increase 5 mg/dose every 3 days to a maximum of 80 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intrathecal: Children and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Screening dosage: 50 mcg for 1 dose and observe for 4-8 hours; very small children may receive 25 mcg; if ineffective, a repeat dosage increased by 50% (eg, 75 mcg) may be repeated in 24 hours; if still suboptimal, a third dose increased by 33% (eg, 100 mcg) may be repeated in 24 hours; patients who do not respond to 100 mcg intrathecally should not be considered for continuous chronic administration via an implantable pump",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maintenance dose: Continuous infusion: Initial: Depending upon the screening dosage and its duration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     If the screening dose duration &gt;8 hours: Daily dose = effective screening dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     If the screening dose duration &lt;8 hours: Daily dose =",
"     <b>",
"      twice",
"     </b>",
"     effective screening dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Continuous infusion dose mcg/hour = daily dose divided by 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Further adjustments in infusion rate may be done every 24 hours as needed; for spinal cord-related spasticity, increase in 10% to 30% increments/24 hours;  for spasticity of cerebral origin, increase in 5% to 10% increments/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Average daily dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &le;12 years: 100-300 mcg/day (4.2-12.5 mcg/hour); doses as high as 1000 mcg/day have been used",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &gt;12 years and Adults: 300-800 mcg/day (12.5-33 mcg/hour); doses as high as 2000 mcg/day have been used",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F138875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, intrathecal [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gablofen&reg;: 500 mcg/mL (20 mL); 1000 mcg/mL (20 mL); 2000 mcg/mL (20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lioresal&reg;: 500 mcg/mL (20 mL); 2000 mcg/mL (5 mL, 20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, intrathecal [for screening, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gablofen&reg;: 50 mcg/mL (1 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lioresal&reg;: 50 mcg/mL (1 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 10 mg, 20 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F138861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Tablets",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1056753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer with food or milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: Intrathecal: Test dosage: Use dilute concentration (50 mcg/mL) and inject over at least 1 minute; for maintenance infusion via implantable infusion pump, concentrations of 500-2000 mcg/mL may be used; do not abruptly discontinue intrathecal baclofen administration",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F138949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in sterile, preservative-free NS.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1056752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of cerebral spasticity, reversible spasticity associated with multiple sclerosis or spinal cord lesions; intrathecal use for the management of spasticity in patients who are unresponsive to oral baclofen or experience intolerable CNS side effects; treatment of trigeminal neuralgia; adjunctive treatment of tardive dyskinesia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F138951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Baclofen may be confused with Bactroban&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Lioresal&reg; may be confused with lisinopril, Lotensin&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication (intrathecal administration) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F138948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Ataxia, confusion, dizziness, drowsiness, fatigue, headache, hypotonia, insomnia, psychiatric disturbances, slurred speech, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Polyuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Chest pain, dyspnea, dysuria, enuresis, hematuria, impotence, inability to ejaculate, nocturia, palpitation, syncope, urinary retention; withdrawal reactions have occurred with abrupt discontinuation (particularly severe with intrathecal use).",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1056758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to baclofen or any component; injection for intrathecal use is not recommended or intended for I.V., I.M., SubQ, or epidural administration",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1056742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with seizure disorder, impaired renal function, peptic ulcer disease, stroke, ovarian cysts, psychotic disorders, autonomic dysreflexia (intrathecal therapy); careful attention to programming and monitoring of intrathecal baclofen is recommended to prevent abrupt discontinuation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1056741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should not be used when spasticity is used to maintain posture or balance; due to the life-threatening complications of intrathecal use, physicians must be adequately trained in its use; abrupt withdrawal of oral baclofen has been reported to precipitate hallucinations and/or seizures. Abrupt discontinuation of intrathecal baclofen regardless of the cause, has resulted in sequelae that include high fever, altered mental status, exaggerated rebound spasticity, and muscle rigidity, that in rare cases, has advanced to rhabdomyolysis, multiple organ system failure, and death",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Early symptoms of withdrawal include: Return of baseline spasticity, pruritus, hypotension, and paresthesias. Clinical characteristics of advanced withdrawal may resemble autonomic dysreflexia, sepsis, malignant hyperthermia, neuroleptic-malignant syndrome, and other conditions associated with hypermetabolic state or widespread rhabdomyolysis. Patients at increased risk those include spinal cord injuries at T-6 or above, those with communication difficulties, and those history of withdrawal symptoms from oral baclofen. If restoration of intrathecal baclofen is delayed, oral baclofen or benzodiazepine treatment may be used as a temporary measure.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F138870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F138872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13273272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies. Withdrawal symptoms in the neonate were noted in a case report following the maternal use of oral baclofen 20 mg 4 times/day throughout pregnancy (Ratnayaka, 2001). Plasma concentrations following administration of intrathecal baclofen are significantly less than those with oral doses; exposure to the fetus is expected to be limited (Morton, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1056748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Muscle rigidity, spasticity (decrease in number and severity of spasms), modified Ashworth score",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1056740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits the transmission of both monosynaptic and polysynaptic reflexes at the spinal cord level, possibly by hyperpolarization of primary afferent fiber terminals, with resultant relief of muscle spasticity",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1056756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Muscle relaxation effects require 3-4 days and maximal clinical effects are not seen for 5-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intrathecal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bolus:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Onset of action: 30 minutes to 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maximum effect: 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Duration: 4-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Continuous intrathecal infusion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Onset of action: 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maximum activity: 24-48 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1056757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Absorption: Rapid; absorption from the GI tract is thought to be dose dependent",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Protein binding: 30%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metabolism: Minimal in the liver (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Half-life: 2.5-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Time to peak serum concentration: Oral: Within 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Elimination: 85% of dose excreted in urine and feces as unchanged drug",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intrathecal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Half-life, CSF elimination: 1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance, CSF: 30 mL/hour",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1056747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/48/41732?source=see_link\">",
"      see \"Baclofen: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid alcohol and other CNS depressants; may cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause dry mouth; do not abruptly discontinue therapy",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F138880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 5 mg/mL oral suspension may be made with tablets. Crush thirty 20 mg tablets in a mortar and reduce to a fine powder. Add a small amount of glycerin and mix to a uniform paste. Mix while adding Simple Syrup, NF in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     120 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add a sufficient quantity of vehicle to make 120 mL. Label &ldquo;shake well&rdquo; and &ldquo;refrigerate&rdquo;. Stable for 35 days (Johnson, 1993).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A 10 mg/mL oral suspension may be made with tablets. Crush one-hundred-twenty 10 mg tablets in a mortar and reduce to a fine powder. Add small portions (60 mL) of a 1:1 mixture of Ora-Sweet&reg; and Ora-Plus&reg; and mix to a uniform paste; mix while adding the vehicle in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     120 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 120 mL. Label &ldquo;shake well&rdquo; and &ldquo;refrigerate&rdquo;. Stable for 60 days (Allen, 1996).",
"    </p>",
"    <div class=\"reference\">",
"     Allen LV Jr and Erickson MA 3rd, \"Stability of Baclofen, Captopril, Diltiazem Hydrochloride, Dipyridamole, and Flecainide Acetate in Extemporaneously Compounded Oral Liquids,\"",
"     <i>",
"      Am J Health Syst Pharm",
"     </i>",
"     , 1996, 53(18):2179-84.",
"     <span class=\"pubmed-id\">",
"      8879325",
"     </span>",
"    </div>",
"    <div class=\"reference\">",
"     Johnson CE and Hart SM, &ldquo;Stability of an Extemporaneously Compounded Baclofen Oral Liquid,&rdquo;",
"     <i>",
"      Am J Hosp Pharm",
"     </i>",
"     , 1993, 50(11):2353-5.",
"     <span class=\"pubmed-id\">",
"      8266961",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Albright AL, \"Baclofen in the Treatment of Cerebral Palsy,\"",
"      <i>",
"       J Child Neurol",
"      </i>",
"      , 1996, 11(2):77-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/44/7878/abstract-text/8881981/pubmed\" id=\"8881981\" target=\"_blank\">",
"        8881981",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lubsch L, Habersang R, Haase M, et al, \"Oral Baclofen and Clonidine for Treatment of Spasticity in Children,\"",
"      <i>",
"       J Child Neurol",
"      </i>",
"      , 2006, 21(12):1090-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/44/7878/abstract-text/17156708/pubmed\" id=\"17156708\" target=\"_blank\">",
"        17156708",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Milla PJ and Jackson AD, \"A Controlled Trial of Baclofen in Children With Cerebral Palsy,\"",
"      <i>",
"       J Int Med Res",
"      </i>",
"      , 1977, 5(6):398-404.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/44/7878/abstract-text/338390/pubmed\" id=\"338390\" target=\"_blank\">",
"        338390",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scheinberg A, Hall K, Lam LT, et al, \"Oral Baclofen in Children With Cerebral Palsy: A Double-Blind Cross-Over Pilot Study,\"",
"      <i>",
"       J Paediatr Child Health",
"      </i>",
"      , 2006, 42(11):715-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/44/7878/abstract-text/17044900/pubmed\" id=\"17044900\" target=\"_blank\">",
"        17044900",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12983 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-E8883028DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_44_7878=[""].join("\n");
var outline_f7_44_7878=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708644\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138898\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138899\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056749\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056743\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138875\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138861\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056753\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138949\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056752\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138951\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138948\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056758\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056742\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056741\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298810\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138870\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138872\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13273272\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056748\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056740\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056756\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056757\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056747\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138880\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12983\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12983|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/31/36342?source=related_link\">",
"      Baclofen: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/48/41732?source=related_link\">",
"      Baclofen: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_44_7879="Isradipine: Pediatric drug information";
var content_f7_44_7879=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Isradipine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?0/56/903?source=see_link\">",
"    see \"Isradipine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?26/4/26692?source=see_link\">",
"    see \"Isradipine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10095388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      DynaCirc CR&reg; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1020781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihypertensive Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Calcium Channel Blocker",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Calcium Channel Blocker, Dihydropyridine",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1020815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/56/903?source=see_link\">",
"      see \"Isradipine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: Limited information exists; dose is not well established; only 3 retrospective pediatric studies have been published (Flynn, 2002; Johnson, 1997; Strauser, 2000); further studies are needed. Some experts recommend the following:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release capsules (or extemporaneously prepared suspension): Initial: 0.05-0.15 mg/kg/dose given 3-4 times/day; titrate dose to response; usual dose: 0.3-0.4 mg/kg/day divided every 8 hours; maximum dose 0.8 mg/kg/day up to 20 mg/day (Flynn, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Controlled release tablet: Children who receive a total daily dose of 5 or 10 mg of an immediate release formulation may be switched to an equivalent daily dose of the controlled release tablets administered once or twice daily (Flynn, 2002).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release capsules: Initial: 2.5 mg twice daily; titrate dose to response; may increase dose in increments of 5 mg/day at 2-4 week intervals; usual dosage range (JNC 7): 2.5-10 mg/day in 2 divided doses; maximum: 20 mg/day;",
"     <b>",
"      Note:",
"     </b>",
"     Most patients do not have any additional response to doses &gt;10 mg/day, but may have increased adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Controlled release tablet: Initial: 5 mg once daily; titrate dose to response; may increase dose in increments of 5 mg/day at 2-4 week intervals; maximum: 20 mg/day;",
"     <b>",
"      Note:",
"     </b>",
"     Doses &gt;10 mg/day are associated with increased adverse effects.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F185303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 2.5 mg, 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, controlled release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DynaCirc CR&reg;: 5 mg [DSC], 10 mg [DSC]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F185290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Capsule",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1020819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to meals; swallow controlled release tablet whole, do not crush, break, chew, or divide.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F2935792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsules: Store at controlled room temperature; dispense in a tight, light-resistant container",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Controlled release tablets: Store below 30&deg;C (86&deg;F), in a tight container; protect from moisture and humidity",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1020782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F185376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       DynaCirc&reg; may be confused with Dynacin&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F185374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest pain, edema (dose related), palpitation (dose related), flushing, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, fatigue (dose related), flushing, headache (dose related)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal discomfort, diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Urinary frequency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Angioedema, atrial fibrillation, back pain, constipation, cough, cramps of legs and feet, depression, drowsiness, drug fever, dry mouth, dysuria, epistaxis, gingival hyperplasia (incidence unknown), heart failure, hyperhidrosis, hypotension, impotence, insomnia, joint pain, leg pain, lethargy, leukopenia, libido decreased, liver function tests increased, MI, nasal congestion, nervousness, nocturia, numbness, paresthesia, pruritus, stroke, syncope, throat discomfort, transient ischemic attack, urticaria, ventricular fibrillation, visual disturbance, weight gain",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1020786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to isradipine or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F2935791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Use with caution in patients with CHF or hepatic dysfunction. Use controlled release tablets with caution in patients with severe GI narrowing (obstructive symptoms have occurred in patients with GI strictures after ingestion of other nondeformable controlled release products). Safety and efficacy have not been established in pediatric patients.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1020787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic hypotension may occur; syncope and severe dizziness have been rarely reported, especially after initiation of recommended doses. May cause negative inotropic effects in some patients (use with caution in patients with CHF, especially when used in combination with beta-blockers). Dose-related peripheral edema may occur (use caution in differentiating this adverse effect from decreasing left ventricular function in patients with CHF).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Capsules may contain benzyl alcohol which may cause allergic reactions in susceptible individuals; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (\"gasping syndrome\") in neonates; the \"gasping syndrome\" consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse; use isradipine capsules containing benzyl alcohol with caution in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate, a metabolite of benzyl alcohol, displaces bilirubin from protein binding sites",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F185363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F185299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Management: Concurrent use of felodipine or nisoldipine with itraconazole is specifically contraindicated.  Frequent monitoring is warranted with any such combination; calcium channel blocker dose reductions may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atosiban: Calcium Channel Blockers may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Calcium Channel Blockers. Management: Monitor for decreased therapeutic effects of calcium channel blockers with concomitant barbiturate therapy. Calcium channel blocker dose adjustments may be necessary. Nimodipine Canadian labeling contraindicates concomitant use with phenobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Calcium Channel Blockers (Dihydropyridine) may enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): Calcium Channel Blockers (Dihydropyridine) may enhance the hypotensive effect of Calcium Channel Blockers (Nondihydropyridine). Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May diminish the therapeutic effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Calcium Channel Blockers (Dihydropyridine). Management: Consider calcium channel blocker (CCB) dose adjustments or alternative therapy  in patients receiving concomitant carbamazepine. Nimodipine Canadian labeling contraindicates concurrent use with carbamazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of Calcium Channel Blockers. Management: Consider alternatives to cimetidine. If no suitable alternative exists, monitor for increased effects of calcium channel blockers following cimetidine initiation/dose increase, and decreased effects following cimetidine discontinuation/dose decrease.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: Calcium Channel Blockers may diminish the therapeutic effect of Clopidogrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Calcium Channel Blockers may increase the serum concentration of Fosphenytoin.  Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Calcium Channel Blockers. Management: Consider using a noninteracting macrolide. Monitor for increased therapeutic effects of calcium channel blockers if an interacting macrolide antibiotic is initiated, or decreased effects if a macrolide is discontinued.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: Calcium Channel Blockers may enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypotensive effect of Antihypertensives. MAO Inhibitors may enhance the orthostatic hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Melatonin: May diminish the antihypertensive effect of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nafcillin: May increase the metabolism of Calcium Channel Blockers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): Calcium Channel Blockers may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitroprusside: Calcium Channel Blockers may enhance the hypotensive effect of Nitroprusside.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Calcium Channel Blockers may increase the serum concentration of Phenytoin.  Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). Calcium Channel Blockers (Dihydropyridine) may decrease the serum concentration of QuiNIDine. Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers. Management: The labeling for some U.S. and Canadian calcium channel blockers contraindicate use with rifampin however recommendations vary. Consult appropriate labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1020801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsules: Food decreases the rate, but not the extent of absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Controlled release tablets: Food decreases bioavailability by up to 25%",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F185300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F185314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. Israpidine crosses the human placenta. There are no adequate and well-controlled studies in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2935835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Blood pressure, heart rate, liver and renal function",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1020802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits calcium ions from entering the &ldquo;slow channels&rdquo; or select voltage-sensitive areas of vascular smooth muscle and myocardium during depolarization; produces a relaxation of coronary vascular smooth muscle and coronary vasodilation; increases myocardial oxygen delivery in patients with vasospastic angina",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F2935793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release capsule: ~1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Controlled release tablet: 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect:",
"     <b>",
"      Note:",
"     </b>",
"     Full hypotensive effect may not occur for 2-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release capsule (single dose): 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Controlled release tablet (single dose): 8-10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release capsule: &gt;12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Controlled release tablet: 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1020804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: 90% to 95%, but large first-pass effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     (apparent): 3 L/kg; crosses the placenta",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive first-pass effect; hepatically metabolized via cytochrome P450 isoenzyme CYP3A4; major metabolic pathways include oxidation and ester cleavage; six inactive metabolites have been identified",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: 15% to 24%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Patients with renal dysfunction (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-80 mL/minute): Increased by 45%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Patients with severe renal failure (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute) who are on hemodialysis: Decreased by 20% to 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Patients with hepatic impairment: Increased by 52%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Alpha half-life: 1.5-2 hours; terminal half-life: 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release capsule: 1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Controlled release tablet: Plateaus between 7-18 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 60% to 65% of the dose is eliminated in the urine (none as unchanged drug); 25% to 30% in the feces",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Not significantly removed by hemodialysis (supplemental dose not required)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1020823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?26/4/26692?source=see_link\">",
"      see \"Isradipine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause dizziness and impair ability to perform activities requiring mental alertness or physical coordination. Do not discontinue abruptly. Report unrelieved headache, dizziness, shortness of breath, rapid heart beat, chest pain, swelling of extremities, or sudden weight gain. Some medicines may interact with isradipine; report the use of other medications, nonprescription medications, and herbal or natural products to your physician and pharmacist; avoid the herbal medicine St John's wort. Empty controlled release tablets may appear in stool after medication is absorbed (this is normal).",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F2935837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     DynaCirc&reg; CR is an osmotic controlled-release formulation; the tablet is nondeformable; drug is released from the tablet at a constant rate that is dependent on the osmotic gradient between the contents of the bilayer active drug core of the tablet and the fluid in the GI tract; drug release is independent of pH or GI motility.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F185309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 1 mg/mL oral suspension may be made from isradipine capsules; glycerin, USP; and Simple Syrup, N.F. Empty the contents of ten 5 mg isradipine capsules into a glass mortar. Add a small portion of glycerin, USP and mix to a fine paste; mix while adding 15 mL of simple syrup and transfer contents to a 60 mL amber glass prescription bottle. Rinse mortar with 10 mL simple syrup, NF and transfer to the prescription bottle; repeat, and add quantity of vehicle sufficient to make 50 mL. Label \"protect from light\", \"refrigerate\", and \"shake well\". Stable for 35 days when stored in amber glass prescription bottles in the dark and refrigerated.",
"    </p>",
"    <div class=\"reference\">",
"     MacDonald JL, Johnson CE, and Jacobson P, &ldquo;Stability of Isradipine in Extemporaneously Compounded Oral Liquids,&rdquo;",
"     <i>",
"      Am J Hosp Pharm",
"     </i>",
"     , 1994, 51(19):2409-11.",
"     <span class=\"pubmed-id\">",
"      7847406",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ahmed K, Michael B, and Burke JF Jr, \"Effects of Isradipine on Renal Hemodynamics in Renal Transplant Patients Treated With Cyclosporine,\"",
"      <i>",
"       Clin Nephrol",
"      </i>",
"      , 1997, 48(5):307-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/44/7879/abstract-text/9403215/pubmed\" id=\"9403215\" target=\"_blank\">",
"        9403215",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/44/7879/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Flynn JT and Pasko DA, \"Calcium Channel Blockers: Pharmacology and Place in Therapy of Pediatric Hypertension,\"",
"      <i>",
"       Pediatr Nephrol",
"      </i>",
"      , 2000, 15(3-4):302-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/44/7879/abstract-text/11149130/pubmed\" id=\"11149130\" target=\"_blank\">",
"        11149130",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Flynn JT and Warnick SJ, \"Isradipine Treatment of Hypertension in Children: A Single-Center Experience,\"",
"      <i>",
"       Pediatr Nephrol",
"      </i>",
"      , 2002, 17(9):748-53.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Johnson CE, Jacobson PA, and Song MH, \"Isradipine Therapy in Hypertensive Pediatric Patients,\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1997, 31(6):704-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/44/7879/abstract-text/9184708/pubmed\" id=\"9184708\" target=\"_blank\">",
"        9184708",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McCrea JB, Francos GF, and Burke JF, \"The Beneficial Effects of Isradipine on Renal Hemodynamics in Cyclosporine-Treated Renal Transplant Recipients,\"",
"      <i>",
"       Transplantation",
"      </i>",
"      , 1993, 55(3):672-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/44/7879/abstract-text/8456491/pubmed\" id=\"8456491\" target=\"_blank\">",
"        8456491",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rodicio JL, \"Calcium Antagonists and Renal Protection From Cyclosporine Nephrotoxicity: Long-Term Trial in Renal Transplantation Patients,\"",
"      <i>",
"       J Cardiovasc Pharmacol",
"      </i>",
"      , 2000, 35(3 Suppl 1):S7-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/44/7879/abstract-text/11347860/pubmed\" id=\"11347860\" target=\"_blank\">",
"        11347860",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steele RM, Schuna AA, and Schreiber RT, &ldquo;Calcium Antagonist-Induced Gingival Hyperplasia,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1994, 120(8):663-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/44/7879/abstract-text/8135450/pubmed\" id=\"8135450\" target=\"_blank\">",
"        8135450",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Strauser LM, Groshong T, and Tobias JD, \"Initial Experience With Isradipine for the Treatment of Hypertension in Children,\"",
"      <i>",
"       South Med J",
"      </i>",
"      , 2000, 93(3):287-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/44/7879/abstract-text/10728516/pubmed\" id=\"10728516\" target=\"_blank\">",
"        10728516",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12890 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-641A5F4110-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_44_7879=[""].join("\n");
var outline_f7_44_7879=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10095388\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020781\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020815\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185303\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185290\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020819\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2935792\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020782\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185376\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185374\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020786\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2935791\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020787\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185363\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185299\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020801\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185300\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185314\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2935835\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020802\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2935793\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020804\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020823\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2935837\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185309\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12890\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12890|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/56/903?source=related_link\">",
"      Isradipine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?26/4/26692?source=related_link\">",
"      Isradipine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_44_7880="Miller blade in proper position";
var content_f7_44_7880=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F59270&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F59270&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Miller blade in proper position",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 394px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In this cadaver, the Miller blade is shown lifting the epiglottis to expose the glottis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Orebaugh SL. Retraction blades for direct laryngoscopy. In: Atlas of Airway Management: Techniques and Tools, Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_44_7880=[""].join("\n");
var outline_f7_44_7880=null;
var title_f7_44_7881="Anticoagulant, antiplatelet, and fibrinolytic (thrombolytic) therapy in patients at high risk for ocular hemorrhage";
var content_f7_44_7881=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Anticoagulant, antiplatelet, and fibrinolytic (thrombolytic) therapy in patients at high risk for ocular hemorrhage",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/44/7881/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/44/7881/contributors\">",
"     John E Carter, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/44/7881/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/44/7881/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/44/7881/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/44/7881/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/44/7881/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ocular hemorrhages usually originate from either the retina or the choroid. Normal retinal vessels can be damaged by an acute process (eg, trauma, retinal detachment), or by chronic disorders (eg, diabetes, retinal vein occlusion, sickle cell retinopathy, retinal macroaneurysms and retinal hemangiomas). Complete repair of such damage is not usually accomplished, since retinal neovascularization produces abnormal, fragile vessels prone to hemorrhage.",
"   </p>",
"   <p>",
"    Similarly, choroidal neovascular membranes are abnormal networks of vessels that may complicate pathologic processes involving the retinal pigment epithelium and Bruch's membrane including age-related macular degeneration (ARMD), myopic degeneration, angioid streaks, ocular histoplasmosis, multifocal choroiditis, punctate inner choroidopathy, and choroidal tumors. These membranes are also prone to bleed.",
"   </p>",
"   <p>",
"    Most of the above noted ocular vascular conditions are chronic and are likely to coexist with conditions for which antithrombotic medications are prescribed, raising the question of whether their use might result in ocular hemorrhage. Hemorrhage into the preretinal (subhyaloid) space and vitreous are amenable to surgical treatment with generally good outcome; in comparison, hemorrhage into the retina or choroid is more likely to produce substantial, permanent visual impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7881/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of anticoagulant, antiplatelet, and fibrinolytic therapy in patients at high risk for ocular hemorrhage will be reviewed here. There are a number of other high-risk central nervous system settings in which patients may require anticoagulant or antiplatelet therapy. These issues are discussed separately and include patients with the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A primary or metastatic brain tumor. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/39/30327?source=see_link\">",
"       \"Anticoagulant and antiplatelet therapy in patients with brain tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An acute or prior intracerebral hemorrhage. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8089?source=see_link\">",
"       \"Anticoagulant and antiplatelet therapy in patients with an acute or prior intracerebral hemorrhage\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An unruptured intracranial aneurysm. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/36/33348?source=see_link\">",
"       \"Anticoagulant and antiplatelet therapy in patients with an unruptured intracranial aneurysm\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       Warfarin",
"      </a>",
"      -associated intracerebral hemorrhage. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/12/27849?source=see_link\">",
"       \"Risk of intracerebral hemorrhage in patients treated with warfarin\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10298?source=see_link\">",
"       \"Management of warfarin-associated intracerebral hemorrhage\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INTRAOCULAR BLOOD SUPPLY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The retina is the innermost layer of the eye and receives blood supply and nourishment for its inner two-thirds from the central retinal artery and its branches. The choroid is separated from the retina by Bruch's membrane and is a vascular structure acting to maintain intraocular pressure and also to provide nourishment to the outer one-third of the retina by diffusion across Bruch's membrane. The choroidal blood supply comes from the posterior ciliary arteries, which are the terminal branches of the ophthalmic artery after the central retinal artery leaves to enter the optic nerve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Neovascularization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neovascularization of the retina, seen in diabetes mellitus and other disorders such as retinal vein occlusion and sickle cell anemia, involves the elaboration of angiogenesis factors as a result of retinal ischemia. The cause of choroidal neovascularization is less well understood, and includes theories involving ischemia or oxidative damage [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7881/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ANTIPLATELET AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of antiplatelet agents is associated with an increase in asymptomatic, superficial retinal hemorrhages over the optic disc. This was shown in a study of 32,918 residents of Malmo, Sweden, who were screened for glaucoma and retinal hemorrhage using fundus photography [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7881/abstract/3\">",
"     3",
"    </a>",
"    ]. Only the use of antiplatelet agents was associated with a significant increase in the presence of retinal hemorrhages (odds ratio: 3.2). However, the hemorrhages noted in these photographs would not be expected to produce any clinical signs or symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Diabetic retinopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the information on the use of antiplatelet agents in conditions associated with ocular hemorrhage relates to the treatment of patients with diabetes mellitus. Because ischemia contributes to the ocular complications of diabetes, the use of antiplatelet agents has been evaluated for both possible treatment and for safety of use. In general,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    appears to have",
"    <strong>",
"     no effect",
"    </strong>",
"    (either positive or negative) on the development or progression of proliferative retinopathy, vitreous bleeding, or visual loss. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/38/32362?source=see_link&amp;anchor=H9#H9\">",
"     \"Prevention and treatment of diabetic retinopathy\", section on 'Antiplatelet agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    does not appear to increase hemorrhagic complications in patients with diabetic retinopathy, even if advanced. In the Early Treatment Diabetic Retinopathy Study, patients with mild to severe nonproliferative or early proliferative diabetic retinopathy had one eye treated with scatter retinal photocoagulation. The 3711 participants were also randomly assigned to receive either aspirin (650",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo. During the study, periodic fundus photography of the eyes not receiving photocoagulation detected vitreous or preretinal hemorrhages in 32 versus 30 percent of patients treated with aspirin or placebo, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7881/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 40 percent of these hemorrhages produced a loss of visual acuity to less than",
"    <span class=\"nowrap\">",
"     20/40.",
"    </span>",
"    However, the severity and rate of resolution of these hemorrhages were not different between the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    - and placebo-treated groups.",
"   </p>",
"   <p>",
"    This study, as well as a meta-analysis of other randomized clinical trials, concluded that there were no ocular contraindications to the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (650",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    in persons with diabetes who require this medicine for treatment of cardiovascular disease or for other medical indications [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7881/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/38/32362?source=see_link&amp;anchor=H9#H9\">",
"     \"Prevention and treatment of diabetic retinopathy\", section on 'Antiplatelet agents'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of medical care in adults with diabetes mellitus\", section on 'Aspirin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Age-related macular degeneration",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few studies concerning the safety of antiplatelet agents in age-related macular degeneration (ARMD) and they are conflicting.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      was not associated with more ocular hemorrhage in trials conducted by the Macular Photocoagulation Study Group [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7881/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the Physicians' Health Study, a trend favoring",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      was apparent both for reducing the occurrence of ARMD and for reducing the occurrence of visual loss to",
"      <span class=\"nowrap\">",
"       20/30",
"      </span>",
"      or worse due to ARMD [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7881/abstract/7\">",
"       7",
"      </a>",
"      ]. The beneficial effect of aspirin on prevention of myocardial infarction forced early termination of the trial before its effect on ocular hemorrhage could be adequately assessed.",
"     </li>",
"     <li>",
"      In a retrospective study of 195 eyes of 195 patients with neovascular age-related macular degeneration, 49 percent were taking daily antiplatelet agents (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      ) or anticoagulants (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7881/abstract/8\">",
"       8",
"      </a>",
"      ]. The rates of hemorrhage were 63.5 versus 29.2 percent for those taking or not taking such medications, respectively, with annual bleeding rates of 0.14 and 0.04 percent per year, respectively. The study involved patients identified with neovascularization between 2002 and 2008; current therapy with anti-vascular endothelial growth factor (anti-VEGF) agents was not available until midway through this period. All of these patients would be treated effectively for the neovascularization today. This study did not address patients with ARMD but without neovascularization.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When hemorrhages occur they may be more extensive. A report of 71 consecutive patients with ARMD complicated by acute subretinal hemorrhages found that the size of the hemorrhages was significantly larger in patients receiving antiplatelet agents or anticoagulants. Final visual outcomes were not reported [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7881/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of antiplatelet agents in patients with ARMD overall appears to be safe. With effective anti-VEGF therapy for neovascularization in ARMD available today it seems likely that this statement extends to patients with both non-neovascular and neovascular ARMD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Recommendation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Considering diabetic retinopathy, ARMD, and other ocular conditions predisposing to ocular hemorrhage, the use of antiplatelet agents does not result in increased rates of symptomatic ocular hemorrhage or in a worse outcome in patients who experience an ocular hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     WARFARIN AND OTHER VITAMIN K ANTAGONISTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic anticoagulation with vitamin K antagonists has been successfully employed in a number of clinical settings, despite a relatively high rate of bleeding complications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link&amp;anchor=H28#H28\">",
"     \"Therapeutic use of warfarin\", section on 'Bleeding'",
"    </a>",
"    .) This includes an approximately two- to fivefold increased risk of an initial intracranial hemorrhage (ICH) in elderly patients with achieved INRs of 2.0 to 3.0. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/12/27849?source=see_link&amp;anchor=H2#H2\">",
"     \"Risk of intracerebral hemorrhage in patients treated with warfarin\", section on 'ICH risk with antithrombotic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of ocular hemorrhage in unselected patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is probably low. Of 126 patients from a large anticoagulation clinic who volunteered to undergo direct and indirect ophthalmoscopy, only four (3 percent) had small, visually insignificant, retinal hemorrhages [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7881/abstract/10\">",
"     10",
"    </a>",
"    ]. The authors concluded that the risk of warfarin-induced retinal hemorrhage in patients without preexisting ocular disease, such as retinal neovascularization or choroidal vasculopathy, is so small that it should not deter physicians from prescribing this drug when indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Age-related macular degeneration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of reports concerning ocular hemorrhage during anticoagulation involve patients with age-related macular degeneration (ARMD). ARMD is common; nearly everyone over the age of 50 years has at least one macular drusen, which are localized deposits of extracellular material concentrated in the macula [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7881/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/52/6986?source=see_link&amp;anchor=H2#H2\">",
"     \"Age-related macular degeneration: Clinical presentation, etiology, and diagnosis\", section on 'Definition and classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early ARMD, consisting of large drusen and pigmentary abnormalities, is present in 30 percent of the population over 75 years of age. Advanced ARMD likely to produce visually significant damage is present in 7 percent of this age group. Most patients have the atrophic form (geographic or \"dry\" ARMD), with loss of photoreceptors, retinal pigment epithelium, and the choriocapillaris that may progress and produce mild or moderate visual loss. The remainder, about 10 to 20 percent, develops a central fibrovascular scar that may produce exudation or macular hemorrhage. At least 80 percent of patients with ARMD and vision",
"    <span class=\"nowrap\">",
"     20/200",
"    </span>",
"    or worse have this neovascular or \"wet\" form [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7881/abstract/11-13\">",
"     11-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A report commented on 109 patients &ge;60 years of age with macular hemorrhage who were receiving antithrombotic or antiplatelet medications of some kind [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7881/abstract/14\">",
"     14",
"    </a>",
"    ]. Presumably most of these patients had ARMD, but several had macular hemorrhage without choroidal neovascularization on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    angiography. Six patients were receiving a vitamin K antagonist, while 60 percent of those not receiving a vitamin K antagonist were receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    , or both, with the remainder receiving a variety of other antiplatelet medications. Two problems interfere with interpretation of this information:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No information was provided regarding visual outcome.",
"     </li>",
"     <li>",
"      No information was provided concerning the number of patients seen during the same period who developed macular hemorrhage and were not receiving antithrombotic or antiplatelet medications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of reports have described massive intraocular hemorrhage in ARMD. While unusual, the outcome in these cases is uniformly poor, often with residual vision reduced to the ability to see only hand motions or worse. In those reports with 10 or more patients, an average of 22 percent were receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    (range: zero to 30 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7881/abstract/15-21\">",
"     15-21",
"    </a>",
"    ]. Fifteen of 21 patients, however, came from one study in which all patients had excessive degrees of anticoagulation, with INRs in the range of 3.0 to 4.0 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7881/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the latter case control study of patients with ARMD, 50 patients with massive subretinal hemorrhage were compared with 50 with small subretinal hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7881/abstract/16\">",
"     16",
"    </a>",
"    ]. The percent of patients with massive or small subretinal hemorrhages who were receiving anticoagulation was 30 and 4 percent, respectively (relative risk 11.6). Use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    was not different between the two patient groups.",
"   </p>",
"   <p>",
"    Over one-half of the patients in the massive hemorrhage group were allowed to discontinue anticoagulant medication, suggesting that the indications for this agent may not have been sufficiently stringent. The authors concluded that physicians prescribing anticoagulant medication should be informed about the macular status of the patient. In patients with neovascular (or wet) ARMD, anticoagulant medication should be prescribed only for absolute systemic indications, and overanticoagulation should be strictly avoided through careful monitoring of the INR [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7881/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Recommendation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    and other oral anticoagulants results in increased risk for hemorrhagic complications in ARMD and perhaps other ocular conditions predisposing to ocular hemorrhage, but the absolute risk increase appears to be small. The outcome of preretinal (also called subhyaloid) and vitreous hemorrhage in diabetics is often good with appropriate treatment, but the outcome of subretinal hemorrhages in ARMD is often visually devastating. The advent of effective therapy for neovascularization with anti-VEGF agents may make the use of anticoagulants safer in these patients.",
"   </p>",
"   <p>",
"    Nevertheless, the high risk of stroke and pulmonary embolism in conditions for which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is indicated provides a strong argument for its use despite the small risk of ocular complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     FIBRINOLYTIC AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with acute anticoagulation, there are only anecdotal reports of intraocular bleeding in patients with predisposing retinal conditions who have been treated with fibrinolytic agents [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7881/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Such complications occur in patients without predisposing ocular conditions as well, often with good outcomes following ocular surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7881/abstract/25-28\">",
"     25-28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Diabetic retinopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surveys have shown a variety of approaches among physicians for the use of fibrinolytic agents in patients with diabetes, with no difference in the occurrence of intraocular hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7881/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. In the GUSTO-I trial of almost 41,000 patients, there was only one ocular hemorrhage (eyelid hematoma after a documented fall) and no intraocular hemorrhages among 6011 patients with diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7881/abstract/30\">",
"     30",
"    </a>",
"    ]. It was estimated that about 2000 of the diabetic patients had nonproliferative retinopathy and about 300 had proliferative retinopathy. Although the risk of ocular hemorrhage was not as completely evaluated in other major fibrinolytic trials, an appreciable number of diabetics were included without reports of major intraocular bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7881/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon these findings, the recommendation is that diabetic retinopathy, even if proliferative, should not be considered a contraindication to fibrinolytic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7881/abstract/30-34\">",
"     30-34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Age-related macular degeneration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrinolytic therapy in patients with ARMD may be complicated by ocular hemorrhage. However, no reports of large groups of patients with ARMD treated with thrombolytics are available. One patient with exudative ARMD was reported to have a vitreous hemorrhage in the affected eye three hours after the intravenous administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/25/30101?source=see_link\">",
"     reteplase",
"    </a>",
"    and eventually underwent vitrectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7881/abstract/24\">",
"     24",
"    </a>",
"    ]. Intraocular pressure was treated successfully, but the final visual acuity was only light perception.",
"   </p>",
"   <p>",
"    The visual outcome of ocular hemorrhage in patients with ARMD may not be as good as the outcome of vitreous hemorrhage in diabetics, but there is no reason to expect a substantially higher complication rate in patients with ARMD than in patients with diabetes. Given the serious conditions for which fibrinolytic drugs are given it is reasonable to use them, when indicated, in patients with ARMD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Recommendation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of acute myocardial infarction or stroke with fibrinolytic agents will be uncommonly associated with ocular hemorrhages. The risk does not appear to be different in patients with and without ocular conditions complicated by hemorrhages. These ocular disorders are not a contraindication to the use of fibrinolytic therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41098?source=see_link\">",
"     \"Reperfusion therapy for acute ischemic stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=see_link&amp;anchor=H69242077#H69242077\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\", section on 'Diabetes mellitus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     OPHTHALMIC SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients undergoing elective ophthalmic surgery may be taking antiplatelet or anticoagulant medication. Although use of these agents may increase the risk of bleeding with surgical procedures, interruption of such therapy may increase the risk of stroke or thromboembolism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=see_link\">",
"     \"Management of anticoagulation before and after elective surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This section will review the available information concerning these risks in patients undergoing ophthalmic surgery. A more detailed discussion concerning the use of antithrombotic agents in patients undergoing cataract surgery is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/19/2362?source=see_link&amp;anchor=H17#H17\">",
"     \"Cataract in adults\", section on 'Antithrombotic agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, however, ocular surgical procedures have a very low risk of bleeding. Retinal surgeons manipulating the retina probably have the most hemorrhagic complications, primarily due to mechanical or technical reasons. However, it is not known whether the amount of bleeding that may be encountered is increased if the patient is taking an antithrombotic agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9135936\">",
"    <span class=\"h2\">",
"     Pars plana vitrectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retrospective studies on the incidence of bleeding following pars plana vitrectomy in patients taking antithrombotic medications are contradictory. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A single-center retrospective cohort study evaluated the risk of hemorrhagic complications in 289 consecutive patients undergoing 25-gauge pars plana vitrectomy (PPV). Transient vitreous hemorrhage occurred in 1 of 64 PPV procedures (1.6 percent) in those taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , in 5 of 136 PPV procedures (3.7 percent) in those taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      , and in 4 of 110 PPV procedures (3.6 percent) in those not taking either of these medications. No patient experienced anesthesia-related hemorrhagic complications resulting from peribulbar or retrobulbar block or choroidal or retrobulbar hemorrhage secondary to the PPV procedure itself.",
"     </li>",
"     <li>",
"      In a second report in 139 patients undergoing PPV for diabetic eye disease, eight of 29 patients (27.6 percent) who were still taking anticoagulants or antiplatelet agents at the time of surgery had significant persistent vitreous cavity hemorrhage during the postoperative period, with four (13.8 percent) requiring secondary surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7881/abstract/35\">",
"       35",
"      </a>",
"      ]. For the 39 patients who had discontinued such therapy prior to surgery, these percentages were 10.3 and 7.7 percent, respectively, while for the 87 patients not taking these medications, the rates of bleeding and reoperation were 6.9 and zero percent, respectively.",
"     </li>",
"     <li>",
"      In a third report in 97 eyes operated on for diabetic vitrectomy, there was no difference in the incidence of postoperative vitreous hemorrhage or surgical reoperation between those who remained on anticoagulation and those who stopped this medication prior to surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7881/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The authors of the first and third studies recommended that patients continue taking their current therapeutic regimen without cessation during the procedure. The authors of the second study, while mentioning that preoperative medication cessation appeared to reduce the risks of bleeding and reoperation, emphasized the need for caution when the risk of systemic thrombosis secondary to medication cessation is appreciable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Anticoagulants",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a concern that the use of anticoagulants may increase the likelihood of ocular hemorrhage during most forms of ophthalmic surgery. Available reports concerning such risks are mixed, with some studies showing [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7881/abstract/37-42\">",
"     37-42",
"    </a>",
"    ] and others not showing [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7881/abstract/43-48\">",
"     43-48",
"    </a>",
"    ] an excess bleeding risk following their use. The following observations in illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An early report in 50 patients undergoing ophthalmic surgery showed a significant increase in perioperative hemorrhages in patients who had been receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      compared with a matched control group not receiving this agent (12 versus zero percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7881/abstract/37\">",
"       37",
"      </a>",
"      ]. There was no significant difference in hemorrhagic complications between patients in whom warfarin was continued and those in whom it was discontinued during the perioperative period.",
"     </li>",
"     <li>",
"      A larger study of 541 patients undergoing vitreoretinal surgery indicated an increase in the rate of hemorrhagic complications in patients taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      (relative risk: 6.2) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7881/abstract/38\">",
"       38",
"      </a>",
"      ]. The authors concluded that warfarin may be stopped prior to surgery if the patient's thromboembolic risk is low.",
"     </li>",
"     <li>",
"      A study of 347 patients undergoing glaucoma surgery included 21 patients on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      whose medication was continued and 19 patients whose warfarin was discontinued [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7881/abstract/41\">",
"       41",
"      </a>",
"      ]. Patients on anticoagulants had a significantly higher complication rate than patients on antiplatelet agents or on no medication. Seven patients continuing anticoagulation during surgery had hemorrhagic complications while only 3 patients in whom anticoagulation was discontinued had such complications, but this result did not reach statistical significance.",
"     </li>",
"     <li>",
"      A study of 367 patients undergoing trabeculectomy included only five patients on anticoagulants [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7881/abstract/42\">",
"       42",
"      </a>",
"      ]. However, all five suffered significant hyphema and four had failure of the trabeculectomy within one year.",
"     </li>",
"     <li>",
"      In contrast to these findings, the risk of hemorrhagic complications in patients continuing",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      was not increased in a prospective cohort study of 19,584 cataract surgeries in patients &ge;50 years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7881/abstract/47\">",
"       47",
"      </a>",
"      ]. Among patients routinely taking warfarin prior to surgery, 526 continued warfarin within four days of surgery and 208 discontinued warfarin [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7881/abstract/47\">",
"       47",
"      </a>",
"      ]. There were no ocular hemorrhagic events in either group and no significant differences in overall medical event rates.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similarly, a subsequent study of 48,862 patients undergoing 55,567 cataract operations included 5.1 percent who were taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7881/abstract/48\">",
"     48",
"    </a>",
"    ]. There was an increase in subconjunctival hematoma related to the anesthesia block, but no ocular hemorrhagic complications.",
"   </p>",
"   <p>",
"    In two phase III trials of intravitreal injection of the anti-vascular endothelial growth factor (anti-VEGF) agents",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/40/33413?source=see_link\">",
"     ranibizumab",
"    </a>",
"    , 85 patients had 18 or more intravitreal injections without hemorrhagic complications [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7881/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Recommendation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    for the prevention of major thromboembolic complications can undergo cataract surgery with reasonable safety. However, patients undergoing vitreoretinal and glaucoma surgery may experience an increase in visually significant bleeding complications. The decision to withhold warfarin prior to surgery should be made on an individual basis, depending upon the indication for the anticoagulation. Other factors to consider include whether the patient is monocular or binocular, or has risk factors for ocular hemorrhage, such as prior hemorrhage in the fellow eye.",
"   </p>",
"   <p>",
"    Patients receiving intravitreal injections of anti-VEGF agents may continue anticoagulation safely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Antiplatelet agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of patients receiving antiplatelet agents have shown no adverse effects in those undergoing cataract, glaucoma, or vitreoretinal surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7881/abstract/38,41,42,47,48,50-52\">",
"     38,41,42,47,48,50-52",
"    </a>",
"    ]. The complication rate in patients using or not using antiplatelet agents is very small. Use of antiplatelet drugs may be associated with an increase in minor hemorrhagic complications (eg, subconjunctival hemorrhage) related to retrobulbar block, but no increase in ocular hemorrhage complications and no visually significant complications. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the prospective cohort study of 19,584 cataract surgeries cited above, routine users of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      who continued therapy had the same very low risk of ocular hemorrhage as those who did not use aspirin (0.59 versus 0.56 events per 1000 surgeries) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7881/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a review of 48,862 (55,567 extracted but only 48,862 analyzed in the study) cataract operations, 28.1, 5.1, 1.9, and 1.0 percent of the patients were taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      , respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7881/abstract/48\">",
"       48",
"      </a>",
"      ]. Some patients were on combination antiplatelet therapy. The use of warfarin was associated with a significant increase in minor hemorrhagic complications of the anesthesia, mostly subconjunctival hemorrhage, but no sight-threatening complications and no ocular hemorrhagic complications were noted. Patients taking clopidogrel alone, but not those taking clopidogrel plus aspirin, also had an increase in subconjunctival hemorrhage but did not have visually significant ocular hemorrhagic complications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Recommendation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the above observations, antiplatelet agents can be continued safely in patients undergoing ocular surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24420425\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the ocular vascular conditions affecting the retina or choroid are chronic and are likely to coexist with conditions for which antithrombotic medications are prescribed, raising the question of whether their use might result in ocular hemorrhage. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H2\">",
"     'Intraocular blood supply'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Diabetic retinopathy",
"      </strong>",
"      &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      appears to have no effect (either positive or negative) on the development or progression of proliferative retinopathy, vitreous bleeding, or visual loss. Similarly, diabetic retinopathy, even if proliferative, should not be considered a contraindication to fibrinolytic therapy. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diabetic retinopathy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/38/32362?source=see_link&amp;anchor=H9#H9\">",
"       \"Prevention and treatment of diabetic retinopathy\", section on 'Antiplatelet agents'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Age-related macular degeneration",
"      </strong>",
"      &mdash; The use of antiplatelet agents does not result in increased rates of symptomatic ocular hemorrhage in this condition and may reduce progression of the ocular pathology in some situations. This condition is not a contraindication to the use of fibrinolytic therapy. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Age-related macular degeneration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Ophthalmic surgery",
"      </strong>",
"      &mdash; Patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      for the prevention of major thromboembolic complications can undergo cataract surgery with reasonable safety. However, patients undergoing vitreoretinal and glaucoma surgery may experience an increase in visually significant bleeding complications, but these are likely to be amenable to treatment. Antiplatelet agents can be continued safely in patients undergoing ocular surgery. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Ophthalmic surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The use of oral anticoagulants is presumably limited to patients with medical conditions that have potential severe morbidity or mortality that justify the use of these drugs with their significant risk. Discontinuation of oral anticoagulants for ocular surgery in these patients is generally not recommended. Antiplatelet agents are widely used, often for unclear reasons. However, patients with established coronary artery disease, cerebrovascular disease, recent vascular stent placement and other well-defined indications may continue such medications with minimal risk of clinically significant ocular hemorrhagic complications. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=see_link&amp;anchor=H3#H3\">",
"       \"Management of anticoagulation before and after elective surgery\", section on 'Thrombotic risk if anticoagulation is stopped'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=see_link&amp;anchor=H7#H7\">",
"       \"Management of anticoagulation before and after elective surgery\", section on 'Bleeding risk if anticoagulation is continued'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/1\">",
"      Yang SS, Fu AD, McDonald HR, et al. Massive spontaneous choroidal hemorrhage. Retina 2003; 23:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/2\">",
"      Spaide RF, Armstrong D, Browne R. Continuing medical education review: choroidal neovascularization in age-related macular degeneration--what is the cause? Retina 2003; 23:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/3\">",
"      Gr&oslash;dum K, Heijl A, Bengtsson B. Optic disc hemorrhages and generalized vascular disease. J Glaucoma 2002; 11:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/4\">",
"      Chew EY, Klein ML, Murphy RP, et al. Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20. Arch Ophthalmol 1995; 113:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/5\">",
"      Bergerhoff K, Clar C, Richter B. Aspirin in diabetic retinopathy. A systematic review. Endocrinol Metab Clin North Am 2002; 31:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/6\">",
"      Klein ML. Macular degeneration: is aspirin a risk for progressive disease? JAMA 1991; 266:2279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/7\">",
"      Christen WG, Glynn RJ, Ajani UA, et al. Age-related maculopathy in a randomized trial of low-dose aspirin among US physicians. Arch Ophthalmol 2001; 119:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/8\">",
"      Kiernan DF, Hariprasad SM, Rusu IM, et al. Epidemiology of the association between anticoagulants and intraocular hemorrhage in patients with neovascular age-related macular degeneration. Retina 2010; 30:1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/9\">",
"      Kuhli-Hattenbach C, Fischer IB, Schalnus R, Hattenbach LO. Subretinal hemorrhages associated with age-related macular degeneration in patients receiving anticoagulation or antiplatelet therapy. Am J Ophthalmol 2010; 149:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/10\">",
"      Superstein R, Gomolin JE, Hammouda W, et al. Prevalence of ocular hemorrhage in patients receiving warfarin therapy. Can J Ophthalmol 2000; 35:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/11\">",
"      Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 1992; 99:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/12\">",
"      Ferris FL 3rd. Senile macular degeneration: review of epidemiologic features. Am J Epidemiol 1983; 118:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/13\">",
"      Bressler NM, Bressler SB, Fine SL. Age-related macular degeneration. Surv Ophthalmol 1988; 32:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/14\">",
"      Kingham JD, Chen MC, Levy MH. Macular hemorrhage in the aging eye: the effects of anticoagulants. N Engl J Med 1988; 318:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/15\">",
"      Weir CR, Nolan DJ, Holding D, Hammer H. Intraocular haemorrhage associated with anticoagulant therapy. Acta Ophthalmol Scand 2000; 78:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/16\">",
"      Tilanus MA, Vaandrager W, Cuypers MH, et al. Relationship between anticoagulant medication and massive intraocular hemorrhage in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2000; 238:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/17\">",
"      el Baba F, Jarrett WH 2nd, Harbin TS Jr, et al. Massive hemorrhage complicating age-related macular degeneration. Clinicopathologic correlation and role of anticoagulants. Ophthalmology 1986; 93:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/18\">",
"      Raj A, Sekhri R, Salam A, Priya P. Massive subretinal bleed in a patient with background diabetic retinopathy and on treatment with warfarin. Eye (Lond) 2003; 17:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/19\">",
"      Fine SL, Berger JW, Maguire MG, Ho AC. Age-related macular degeneration. N Engl J Med 2000; 342:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/20\">",
"      Kreiger AE, Haidt SJ. Vitreous hemorrhage in senile macular degeneration. Retina 1983; 3:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/21\">",
"      Wood WJ, Smith TR. Senile disciform macular degeneration complicated by massive hemorrhagic retinal detachment and angle closure glaucoma. Retina 1983; 3:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/22\">",
"      Lewis H, Sloan SH, Foos RY. Massive intraocular hemorrhage associated with anticoagulation and age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 1988; 226:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/23\">",
"      Berry C, Weir C, Hammer H. A case of intraocular haemorrhage secondary to thrombolytic therapy. Acta Ophthalmol Scand 2002; 80:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/24\">",
"      Djalilian AR, Cantrill HC, Samuelson TW. Intraocular hemorrhage after systemic thrombolytic therapy in a patient with exudative macular degeneration. Eur J Ophthalmol 2003; 13:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/25\">",
"      Grekos ZG, Schocken DD. Bilateral vitreous hemorrhages as a consequence of thrombolytic therapy successfully treated with vitrectomy in a patient without diabetes. Am Heart J 1995; 130:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/26\">",
"      Manuchehri K, Loo A, Ramchandani M, Kirkby GR. Acute suprachoroidal haemorrhage in a patient treated with streptokinase for myocardial infarction. Eye (Lond) 1999; 13 ( Pt 5):685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/27\">",
"      Khawly JA, Ferrone PJ, Holck DE. Choroidal hemorrhage associated with systemic tissue plasminogen activator. Am J Ophthalmol 1996; 121:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/28\">",
"      Chorich LJ, Derick RJ, Chambers RB, et al. Hemorrhagic ocular complications associated with the use of systemic thrombolytic agents. Ophthalmology 1998; 105:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/29\">",
"      Higgs ER, Parfitt VJ, Harney BA, Hartog M. Use of thrombolysis for acute myocardial infarction in the presence of diabetic retinopathy in the UK, and associated ocular haemorrhagic complications. Diabet Med 1995; 12:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/30\">",
"      Mahaffey KW, Granger CB, Toth CA, et al. Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. J Am Coll Cardiol 1997; 30:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/31\">",
"      Ward H, Yudkin JS. Thrombolysis in patients with diabetes. BMJ 1995; 310:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/32\">",
"      Fava S, Azzopardi J, Muscat HA, Fenech FF. Thrombolysis in patients with diabetes. Risk of intraocular haemorrhage remains unknown. BMJ 1995; 310:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/33\">",
"      Newman DK, Snead MP, Flanagan DW, Scott JD. Thrombolysis in patients with diabetes. More evidence that the treatment should not necessarily be withheld. BMJ 1995; 310:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/34\">",
"      Moriarty KT. Thrombolysis in patients with diabetes. Prophylaxis with aspirin should be considered. BMJ 1995; 310:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/35\">",
"      Fabinyi DC, O'Neill EC, Connell PP, Clark JB. Vitreous cavity haemorrhage post-vitrectomy for diabetic eye disease: the effect of perioperative anticoagulation and antiplatelet agents. Clin Experiment Ophthalmol 2011; 39:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/36\">",
"      Brown JS, Mahmoud TH. Anticoagulation and clinically significant postoperative vitreous hemorrhage in diabetic vitrectomy. Retina 2011; 31:1983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/37\">",
"      Gainey SP, Robertson DM, Fay W, Ilstrup D. Ocular surgery on patients receiving long-term warfarin therapy. Am J Ophthalmol 1989; 108:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/38\">",
"      Narendran N, Williamson TH. The effects of aspirin and warfarin therapy on haemorrhage in vitreoretinal surgery. Acta Ophthalmol Scand 2003; 81:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/39\">",
"      Tuli SS, WuDunn D, Ciulla TA, Cantor LB. Delayed suprachoroidal hemorrhage after glaucoma filtration procedures. Ophthalmology 2001; 108:1808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/40\">",
"      Arnold PN. Study of acute intraoperative suprachoroidal hemorrhage. J Cataract Refract Surg 1992; 18:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/41\">",
"      Law SK, Song BJ, Yu F, et al. Hemorrhagic complications from glaucoma surgery in patients on anticoagulation therapy or antiplatelet therapy. Am J Ophthalmol 2008; 145:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/42\">",
"      Cobb CJ, Chakrabarti S, Chadha V, Sanders R. The effect of aspirin and warfarin therapy in trabeculectomy. Eye (Lond) 2007; 21:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/43\">",
"      McCormack P, Simcock PR, Tullo AB. Management of the anticoagulated patient for ophthalmic surgery. Eye (Lond) 1993; 7 ( Pt 6):749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/44\">",
"      Morris A, Elder MJ. Warfarin therapy and cataract surgery. Clin Experiment Ophthalmol 2000; 28:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/45\">",
"      Carter K, Miller KM. Phacoemulsification and lens implantation in patients treated with aspirin or warfarin. J Cataract Refract Surg 1998; 24:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/46\">",
"      Kallio H, Paloheimo M, Maunuksela EL. Haemorrhage and risk factors associated with retrobulbar/peribulbar block: a prospective study in 1383 patients. Br J Anaesth 2000; 85:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/47\">",
"      Katz J, Feldman MA, Bass EB, et al. Risks and benefits of anticoagulant and antiplatelet medication use before cataract surgery. Ophthalmology 2003; 110:1784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/48\">",
"      Benzimra JD, Johnston RL, Jaycock P, et al. The Cataract National Dataset electronic multicentre audit of 55,567 operations: antiplatelet and anticoagulant medications. Eye (Lond) 2009; 23:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/49\">",
"      Charles S, Rosenfeld PJ, Gayer S. Medical consequences of stopping anticoagulant therapy before intraocular surgery or intravitreal injections. Retina 2007; 27:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/50\">",
"      Saitoh AK, Saitoh A, Taniguchi H, Amemiya T. Anticoagulation therapy and ocular surgery. Ophthalmic Surg Lasers 1998; 29:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/51\">",
"      Assia EI, Raskin T, Kaiserman I, et al. Effect of aspirin intake on bleeding during cataract surgery. J Cataract Refract Surg 1998; 24:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7881/abstract/52\">",
"      Shuler JD, Paschal JF, Holland GN. Antiplatelet therapy and cataract surgery. J Cataract Refract Surg 1992; 18:567.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1327 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-85.214.214.87-D5DBC4741A-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_44_7881=[""].join("\n");
var outline_f7_44_7881=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24420425\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INTRAOCULAR BLOOD SUPPLY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Neovascularization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ANTIPLATELET AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Diabetic retinopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Age-related macular degeneration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Recommendation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      WARFARIN AND OTHER VITAMIN K ANTAGONISTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Age-related macular degeneration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Recommendation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      FIBRINOLYTIC AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Diabetic retinopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Age-related macular degeneration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Recommendation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      OPHTHALMIC SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9135936\">",
"      Pars plana vitrectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Anticoagulants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Recommendation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Antiplatelet agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Recommendation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24420425\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/52/6986?source=related_link\">",
"      Age-related macular degeneration: Clinical presentation, etiology, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8089?source=related_link\">",
"      Anticoagulant and antiplatelet therapy in patients with an acute or prior intracerebral hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/36/33348?source=related_link\">",
"      Anticoagulant and antiplatelet therapy in patients with an unruptured intracranial aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/39/30327?source=related_link\">",
"      Anticoagulant and antiplatelet therapy in patients with brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/19/2362?source=related_link\">",
"      Cataract in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=related_link\">",
"      Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=related_link\">",
"      Management of anticoagulation before and after elective surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10298?source=related_link\">",
"      Management of warfarin-associated intracerebral hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=related_link\">",
"      Overview of medical care in adults with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/38/32362?source=related_link\">",
"      Prevention and treatment of diabetic retinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41098?source=related_link\">",
"      Reperfusion therapy for acute ischemic stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/12/27849?source=related_link\">",
"      Risk of intracerebral hemorrhage in patients treated with warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=related_link\">",
"      Therapeutic use of warfarin",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_44_7882="Rare complications of ERCP";
var content_f7_44_7882=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Rare complications of ERCP",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/44/7882/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/44/7882/contributors\">",
"     Silvano Loperfido, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/44/7882/contributors\">",
"     Guido Costamagna, MD, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/44/7882/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/44/7882/contributors\">",
"     Douglas A Howell, MD, FASGE, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/44/7882/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/44/7882/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/44/7882/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most frequent complications of ERCP and endoscopic biliary sphincterotomy are pancreatitis, cholangitis, hemorrhage, and duodenal perforation. A number of less common adverse events have also been described including cardiopulmonary complications, contrast allergy, impaction of a retrieval basket and numerous other events reported in only small numbers of patients or individual case reports.",
"   </p>",
"   <p>",
"    This topic review will focus on uncommon and rare complications of ERCP. Complications that occur more frequently are discussed separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uncommon complications of ERCP have been described in several large studies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Miscellaneous complications occurred in 25 of 2347 cases (1 percent) in a prospective series of patients who underwent biliary sphincterotomy [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/1\">",
"       1",
"      </a>",
"      ]. Six of these were cardiopulmonary events, which were fatal in three patients.",
"     </li>",
"     <li>",
"      Similar findings were noted in two Italian prospective series that included a total of 4872 patients undergoing diagnostic and therapeutic ERCP [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/2,3\">",
"       2,3",
"      </a>",
"      ]. Miscellaneous complications were observed in 0.4 to 0.5 percent of patients, more than one-half of which were cardiopulmonary.",
"     </li>",
"     <li>",
"      In a systematic review of 14 prospective studies including a total of 12,973 patients, there were a total of 173 miscellaneous complications (1.3 percent) and nine deaths (0.07 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A Danish study of 39 consecutive claims for compensation due to adverse events included five uncommon complications (back pain after ERCP under general anesthesia, Hashimoto thyroiditis, a fatal case of cholecystitis, tooth injury, and need for repeat uneventful ERCP due to a stone being missed at the first ERCP) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CARDIOPULMONARY AND SEDATION-RELATED COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe respiratory and cardiac side effects of digestive endoscopy are infrequent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/6\">",
"     6",
"    </a>",
"    ]. However, the risk is probably increased with ERCP due to relatively deep sedation, long duration of the examination, prone position of the patient, mean advanced age, and frequent comorbid diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. In a database study that included 6092 ERCPs, there were 129 cardiopulmonary events (2.1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a result, close surveillance of the patient, monitoring of cardiac function and oxygen saturation, aspiration of secretions, administration of flow oxygen when needed, and prompt availability of resuscitation equipment and reversal agents should be part of the routine support during ERCP. Gas embolisms should be considered, among other possibilities, in patients who develop sudden, severe cardiopulmonary events during ERCP. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Portal vein gas, air, and bile embolism'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CONTRAST ALLERGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaphylactic reactions to contrast agents used during ERCP are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/10\">",
"     10",
"    </a>",
"    ]. Nevertheless, a history of sensitivity to iodine contrast or drug should always be considered in the pre-procedure assessment and in the informed consent process.",
"   </p>",
"   <p>",
"    In patients with prior allergy to contrast media, prophylactic measures adopted by most endoscopists include [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Use of",
"      <span class=\"nowrap\">",
"       nonionic/low",
"      </span>",
"      osmolarity contrast media",
"     </li>",
"     <li>",
"      Premedication with oral steroids starting the day before ERCP, or intravenous steroids when allergy is discovered just before the procedure. Some endoscopists also give an intravenous antihistamine in combination with the steroids.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, a study of 601 patients who did not receive prophylaxis (including 80 patients with a documented history of reactions to intravascular contrast media) failed to show any adverse reactions associated with the administration of contrast media [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ELECTROSURGICAL HAZARDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malfunction, incorrect use of electrosurgical equipment and accessories during therapeutic procedures, or defective devices can lead to potentially severe complications of ERCP such as perforation, bleeding, and pancreatitis. Other complications reported in case series include fracture of a Teflon-coated guidewire and retroperitoneal perforation following guidewire-assisted sphincterotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/12,13\">",
"     12,13",
"    </a>",
"    ] and rupture of a metal biliary endoprosthesis following electrocoagulation for tumor ingrowth, a risky maneuver which should be avoided [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Electrocautery can influence implantable devices such as pacemakers and defibrillators. Although most modern pacemakers are unaffected by electrocautery, cardiac arrhythmias can develop if a monopolar current passes through the pacemaker or the heart. The risk is greater for implantable cardioverter-defibrillators since electrocautery may trigger their activation. As a result, the American Society for Gastrointestinal Endoscopy (ASGE) Technology Assessment Committee recommends that implantable cardioverter-defibrillators be deactivated during endoscopic electrosurgery [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EXTRAVASATION OF CONTRAST MEDIUM INTO THE DUODENAL WALL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extravasation of contrast medium into the duodenal wall surrounding the papilla during ERCP can interfere with cannulation and therapeutic procedures, and thereby is a risk factor for complications [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, forceful attempts in cannulation with fine taper catheters or stiff guidewires, especially in patients with bile or pancreatic duct stenosis or those undergoing precut sphincterotomy, can cause transmural false passages and injection of contrast into the retroperitoneal space or vascular structures. A case of septic cholangitis was reported after an inadvertent submucosal contrast injection during a diagnostic ERCP [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     OPACIFICATION OF PORTAL, ARTERIAL, OR LYMPHATIC VESSELS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opacification of the portal vein has been described following sphincterotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/17\">",
"     17",
"    </a>",
"    ], ERCP for pancreatic cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/18,19\">",
"     18,19",
"    </a>",
"    ], needle-knife sphincterotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/20,21\">",
"     20,21",
"    </a>",
"    ], and cannulation of the accessory papilla [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/22\">",
"     22",
"    </a>",
"    ], and documented cases of portal vein visualization during ERCP were reported in patients with pancreatitis (one from a traumatic inadvertent cannulation of the superior mesenteric vein, and another from a preexisting fistula between a pseudocyst and the portal vein) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/23\">",
"     23",
"    </a>",
"    ]. Accidental cannulation of the hepatic artery following needle-knife sphincterotomy has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/24\">",
"     24",
"    </a>",
"    ]. Opacification of the periampullary lymphatic system has also been described following injection of contrast into the pancreatic duct in a patient with pancreatic head carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Filling of portal, arterial, or lymphatic vessels has potential risks, including sepsis, air embolism, bleeding, and thrombosis. Furthermore, failed prompt recognition of contrast in vascular structures may be a source of confusion leading to prolongation of the procedure, thereby further increasing the risk of complications. As an example, an opacified portal vein may be misinterpreted as an incompletely filled bile duct. Insertion of a stent into the portal vein may further worsen the consequences; a case has been reported of placement of an endoscopic nasobiliary drainage tube in the portal vein, fortunately without subsequent complications [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/26\">",
"     26",
"    </a>",
"    ]. In a separate case report, a portobiliary fistula complicating endoscopic stenting was reported in a patient with pancreatic cyst [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DUODENAL PNEUMATOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A limited collection of air within the duodenal wall (duodenal pneumatosis) has been observed following needle-knife sphincterotomy in a patient with biliary obstruction from ampullary tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/28\">",
"     28",
"    </a>",
"    ]. The procedure should be stopped upon recognition of this complication since further bowel manipulation may lead to frank perforation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PORTAL VEIN GAS, AIR, AND BILE EMBOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appearance of gas in the portal venous system is usually a sign of lethal conditions such as advanced intestinal infarction. Portal venous gas has also been observed following ERCP and endoscopic sphincterotomy with a subsequent uneventful course [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/29\">",
"     29",
"    </a>",
"    ] and recovery in a few patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. In one report, portal venous gas was associated with retroperitoneal duodenal perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/33\">",
"     33",
"    </a>",
"    ]. In a report of two patients, air and contrast were visualized in the portal venous system, including a patient with cirrhosis who bled from bile duct varices following therapeutic ERCP [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/18,34\">",
"     18,34",
"    </a>",
"    ]. Other reports have documented fatal cases of hepatic air embolism causing cardiac arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/35-38\">",
"     35-38",
"    </a>",
"    ]. Air probably passed into the portal or hepatic veins from a distended duodenum through a sphincterotomy site or injured duct.",
"   </p>",
"   <p>",
"    Cardiac and cerebral air embolism has also been reported, and a review of 18 reports of air embolism involving 19 patients suggests an increase in the recognition of this problem [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/39\">",
"     39",
"    </a>",
"    ]. Cardiac air embolism has occurred after endoscopic sphincterotomy in a patient with a traumatic biliary fistula [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/40\">",
"     40",
"    </a>",
"    ], following placement of a biliary stent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/41\">",
"     41",
"    </a>",
"    ], after mechanical lithotripsy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/42\">",
"     42",
"    </a>",
"    ], and following cholangioscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/43\">",
"     43",
"    </a>",
"    ]. In these cases, the patients recovered with prompt supportive treatment. In six case reports, arterial air embolism with cerebral ischemia occurred during ERCP; five patients died [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/44-48\">",
"     44-48",
"    </a>",
"    ], and one had a residual hemiparesis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/37\">",
"     37",
"    </a>",
"    ]. In another case report of systemic air embolism, transient myocardial and cerebral ischemia occurred following removal of a bile duct stent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A potential area of concern is the increasing use of direct intraductal endoscopy using small caliber endoscopes (eg, cholangioscopy), which may increase the risk of air embolism. Three cases of air embolism during peroral cholangioscopy with slim endoscopes were reported in Europe, and according to the results of a case series, air insufflation for direct cholangioscopy should not be used, though the use of CO2 appears safe [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/50\">",
"     50",
"    </a>",
"    ]. However, larger studies are needed. The potential risk of intraductal endoscopy should be weighed carefully before such attempts.",
"   </p>",
"   <p>",
"    One report documented a fatality in a patient who had undergone a liver biopsy five days prior to ERCP [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/36\">",
"     36",
"    </a>",
"    ]. Autopsy revealed a fistula between a branch of a hepatic duct and a hepatic vein, suggesting that air introduced into the biliary tree during ERCP had passed through the fistula into the inferior vena cava, leading to an air embolism. Another fatal systemic air embolism was reported in a patient with bile duct stones and a spontaneous biliary duodenal fistula [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/51\">",
"     51",
"    </a>",
"    ]. An autopsy demonstrated a venobiliary fistula secondary to chronic ischemic damage of intrahepatic bile ducts. The incidence of air embolism during ERCP is unknown, but the number of case reports is increasing [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/52-56\">",
"     52-56",
"    </a>",
"    ]. The table illustrates a series of 28 cases reported in the literature (",
"    <a class=\"graphic graphic_table graphicRef77515 \" href=\"UTD.htm?39/60/40911\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Bile embolism has also been described with percutaneous cholangiography [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/57,58\">",
"     57,58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once portal venous air is recognized during ERCP, the procedure should be terminated immediately and the patient should be observed for signs of shock, bleeding, perforation, or sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/35\">",
"     35",
"    </a>",
"    ]. Furthermore, ERCP should be performed extremely cautiously or not at all in patients who are suspected of having a biliary-vascular fistula.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     HEMORRHAGE FROM SPLENIC, HEPATIC OR VASCULAR TRAUMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemorrhage following endoscopic sphincterotomy usually occurs in the duodenal lumen arising from the actual sphincterotomy site. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26216?source=see_link\">",
"     \"Post-ERCP bleeding\"",
"    </a>",
"    .) However, in rare cases intraperitoneal hemorrhage has been described from injury to the spleen, liver, or abdominal vessels.",
"   </p>",
"   <p>",
"    Splenic injury is more commonly caused by colonoscopy but has also been reported following routine upper endoscopy and ERCP. Previous abdominal surgery with adhesion formation is recognized as a risk factor; concomitant liver laceration has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. The severity of the splenic injury varies from a subcapsular hematoma to the avulsion of splenic vessels. As a result, patients do not always present with shock and acute abdomen, and the injury may be overlooked. The diagnosis should be suspected in patients who develop the acute onset of left upper quadrant abdominal pain following ERCP. The pain is often delayed and is not always associated with obvious signs of peritoneal irritation, hemodynamic instability, or a drop in the hematocrit. Definitive diagnosis requires ultrasonography, CT, angiography, laparoscopy, or laparotomy. Surgery is usually required for management.",
"   </p>",
"   <p>",
"    Numerous other bleeding events have been described in case reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One report documented intraperitoneal hemorrhage due to traumatic disruption of the right gastroepiploic artery following endoscopic sphincterotomy and technically difficult stone extraction [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retroperitoneal hematoma occurred as a complication of ERCP after liver transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Transverse mesocolon disruption and ischemic colitis following ERCP with sphincterotomy, and requiring laparotomy and bowel resection [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another report documented an intra-abdominal hematoma following a difficult ERCP requiring prolonged manipulation and long looping of the endoscope in the stomach during the advancement into the duodenum [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An infected liver hematoma following ERCP, probably caused by guidewire use [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A subcapsular liver hematoma following ERCP, probably related to use of guidewire [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/66,67\">",
"       66,67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bleeding from bile duct varices has been described as a complication of ERCP with sphincterotomy and dilatation of a distal common bile duct stricture in a patient with cirrhosis and cavernous transformation of the portal vein [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hemobilia following hydrostatic dilation of stenosis of common bile duct in a patient with hereditary hemorrhagic telangiectasia [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bleeding from a pseudocyst that contained a pseudoaneurysm was reported following nontraumatic cannulation of the pancreatic duct [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A pseudoaneurysm complicating precut-sphincterotomy [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An intrahepatic pseudoaneurysm following ERCP [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A pulsating potentially life-threatening bleed occurred following a needle-knife incision of a swollen papilla in a patient with acute pancreatitis [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/72\">",
"       72",
"      </a>",
"      ]. What had been assumed to be a cystic lesion, on the basis of conventional abdominal ultrasound, was, in fact, a pseudoaneurysm of a branch of the pancreaticoduodenal artery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     RARE SEPTIC COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute cholecystitis and liver abscess are uncommon but well known septic complications of ERCP. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23959?source=see_link\">",
"     \"Post-ERCP septic complications\"",
"    </a>",
"    .) Other rare infectious complications have included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Biliary obstruction and cholangitis due to a blood clot that obstructed the common bile duct after endoscopic sphincterotomy [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/73-75\">",
"       73-75",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pyogenic cholangitis without evidence of biliary tract disease occurred after inadvertent injection of submucosal contrast in the papilla of Vater [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A severe case of retropharyngeal abscess following instrumental injury during ERCP that was reported in the 1970s [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retroperitoneal abscess caused by Haemophilus influenzae and Haemophilus parainfluenzae following pancreatic sphincterotomy and stone extraction [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/77\">",
"       77",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A subcapsular hematoma that occurred during ERCP with sphincterotomy that was complicated by development of a splenic abscess [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/78\">",
"       78",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Abscess formation in a simple renal cyst has been described as a complication of pancreatitis following biliary sphincterotomy [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/79\">",
"       79",
"      </a>",
"      ]. The septic involvement of the renal cyst originated from extrapancreatic collections in the perirenal space.",
"     </li>",
"     <li>",
"      A spinal epidural abscess after endoscopic treatment for chronic pancreatitis [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/80\">",
"       80",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     RARE PERFORATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three types of perforation complicating endoscopic retrograde cholangiopancreatography (ERCP) are most frequently recognized:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Retroperitoneal duodenal perforation",
"     </li>",
"     <li>",
"      Free bowel-wall perforation",
"     </li>",
"     <li>",
"      Perforation of the bile ducts",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of these, retroperitoneal duodenal perforations are the most common. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/38/20072?source=see_link\">",
"     \"Post-ERCP perforation\"",
"    </a>",
"    .) Some less common forms of perforation have also been described:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intestinal perforation related to late biliary stents. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Complications related to biliary and pancreatic stents'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Sigmoid colon perforation as a consequence of bowel air distension and diverticular disease [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/2,81\">",
"       2,81",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cystic duct perforation as a complication of endoscopic stone extraction in a patient with chronic cholecystitis and dense adhesions [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/82\">",
"       82",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Subcutaneous emphysema of the penis and scrotum mimicking gas gangrene secondary to retroperitoneal duodenal perforation [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/83\">",
"       83",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PNEUMOTHORAX, PNEUMOMEDIASTINUM, AND PNEUMOPERITONEUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumothorax, pneumomediastinum, and pneumoperitoneum have been reported secondary to gastrointestinal perforation, including perforation following endoscopic sphincterotomy. However, pneumothorax has also been described during diagnostic upper endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/84,85\">",
"     84,85",
"    </a>",
"    ] and during ERCP without perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/2\">",
"     2",
"    </a>",
"    ]. Such cases are due to a rise in airway and intraalveolar pressure and the rupture of pulmonary blebs.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A case of tension pneumothorax complicating a perforation of a duodenal ulcer during therapeutic ERCP with precut sphincterotomy was reported [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/86\">",
"       86",
"      </a>",
"      ]. Another case of tension pneumothorax was described in a patient with a sealed-off perforated duodenal ulcer and hepatic hydrothorax [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/87\">",
"       87",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another patient developed pneumomediastinum and subcutaneous emphysema, without radiological evidence of perforation, following ERCP with sphincterotomy [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/88\">",
"       88",
"      </a>",
"      ]. The authors' explanation was that air originating in the duodenum dissected interstitially in the absence of a frank perforation.",
"     </li>",
"     <li>",
"      Another report described bilateral pneumothorax, pneumomediastinum, subcutaneous emphysema, pneumoperitoneum, and pneumoretroperitoneum occurred in a patient who underwent endoscopic sphincterotomy and extraction of choledochal stones [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/89\">",
"       89",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A case of tension pneumoperitoneum without perforation was reported after insertion of an endoscopic biliary stent for post-cholecystectomy biliary leak [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/90\">",
"       90",
"      </a>",
"      ]. The authors' explanation was that air passed from the duodenum into the biliary system through the stent and then through the opening in the common bile duct into the peritoneum.",
"     </li>",
"     <li>",
"      Pneumoperitoneum from rupture or intrahepatic bile ducts occurred after ERCP and bile duct stent in a patient with pancreatic cancer and hepatic metastasis [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/91\">",
"       91",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     IMPACTION OF RETRIEVAL BASKETS AND FRACTURE OF THE TRACTION WIRE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impaction of a Dormia basket around a large calculus was a feared complication of bile duct extraction prior to the introduction of mechanical lithotripsy. Despite the availability of lithotripsy, cases are still reported. Usually the basket becomes trapped at the ampulla within the intraduodenal portion of the common bile duct. However, impaction above the intrapancreatic portion of the bile duct, in the intrahepatic ducts, in the main pancreatic duct, and even in the gallbladder has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/92-95\">",
"     92-95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk for basket trapping is increased with big, irregular shaped and hard stones, or multiple stones, in association with small sphincterotomy size. Other risk factors are distal narrowing of the common bile duct and segmental dilatation of intrahepatic ducts as in Caroli's disease.",
"   </p>",
"   <p>",
"    Tailoring the sphincterotomy size appropriately and refraining from fully closing the basket around a large stone may prevent entrapment. In addition, prevention of basket impaction requires experience and good judgment in recognizing conditions in which standard techniques of stone extraction are likely to fail and alternative approaches should be considered.",
"   </p>",
"   <p>",
"    Once the basket impaction has occurred, the first and common alternative is mechanical lithotripsy. Thus, retrieval baskets should always be suitable for mechanical lithotripsy; baskets that are not designed for lithotripsy can fracture. Other non-surgical methods, singularly or in combination, may be effective, including extended sphincterotomy, intracorporeal electrohydraulic lithotripsy (which requires the use of a \"mother and baby\" system or a percutaneous choledochoscopic approach), extracorporeal shock wave lithotripsy, and intracorporeal laser lithotripsy. Surgery is required when these techniques are not available or if they are unsuccessful. Temporary drainage through nasobiliary drain or stent should be provided if the choice of a new option involves a delay. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22905?source=see_link\">",
"     \"Endoscopic management of bile duct stones: Standard techniques and mechanical lithotripsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     COMPLICATIONS RELATED TO BILIARY AND PANCREATIC STENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Plastic biliary and pancreatic stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;A common and generally late complication related to biliary and pancreatic stents is occlusion [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/96\">",
"     96",
"    </a>",
"    ]. Plastic stent insertion may also contribute to the development of post-ERCP pancreatitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42072?source=see_link\">",
"     \"Overview of pancreatic stenting and its complications\"",
"    </a>",
"    .) Uncommon complications are misplacement, dislodgement, and fracture, the latter being generally due to attempts at removal and replacement of the stent.",
"   </p>",
"   <p>",
"    Inadvertent primary misplacement of plastic biliary stents into the retroperitoneum or into an intrahepatic extrabiliary position can occur in patients with malignant bile duct obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/97\">",
"     97",
"    </a>",
"    ]. Duodenal wall ulceration and perforation resulting from pressure necrosis have been observed by several authors following the long-term use of straight prostheses with a long distal intraduodenal part [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/98-103\">",
"     98-103",
"    </a>",
"    ]. A biliocutaneous fistula and a duodenoscrotal fistula have been described following distal migration of long biliary stents [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/104,105\">",
"     104,105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Impaction and perforation of the gut in sites distant from duodenum, especially at the level of sigmoid diverticula, have also been reported by several authors [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/106,107\">",
"     106,107",
"    </a>",
"    ]. A complex colovesicular fistula has been reported as a late severe complication caused by distal migration of a biliary stent placed for choledocholithiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/108,109\">",
"     108,109",
"    </a>",
"    ]. Proximal or distal stent migration has been described in 5 to 7 percent of patients after placement of a plastic biliary stent and 5 to 8 percent of patient after placement of a pancreatic stent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/110\">",
"     110",
"    </a>",
"    ]. As a result, patients should be monitored for stent migration and stents should be removed orally [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The endoscopic retrieval of proximally migrated biliary and pancreatic stents can be technically challenging or unsuccessful [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/112-114\">",
"     112-114",
"    </a>",
"    ]. One study described a late distal perforation of the common bile duct by the distal tip of a migrated straight endoprosthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/115\">",
"     115",
"    </a>",
"    ]. Two cases of bile duct-duodenum and a pancreatic-gastric fistula were reported secondary to proximal migration respectively of a biliary and a pancreatic stent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/116\">",
"     116",
"    </a>",
"    ]. Cases of pleurobiliary fistula following intrahepatic biliary stent migration have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/117\">",
"     117",
"    </a>",
"    ]. A hepaticogastric fistulation has been described as a late complication from a proximally migrated long biliary stent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/118\">",
"     118",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One report described a pancreatic fistula without pancreatitis after endoscopic biliary stent placement for large bile leak in two patients with orthotopic liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/119\">",
"     119",
"    </a>",
"    ]. The authors suggested that placement of a large diameter biliary stent without previous sphincterotomy caused relative obstruction of the pancreatic orifice at the papilla and retrograde flux of pancreatic juice into the bile duct. Acute portal vein thrombosis and massive necrosis of the liver occurred after stenting for chronic pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/120\">",
"     120",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Metal stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other than occlusion by tumor ingrowth, complications related to self expandable metal biliary stents are less frequent than for plastic stents, in part because they have been relatively recently introduced, and are less commonly used. In addition, most patients who receive a metal stent have a limited life expectancy since they are typically placed for malignant obstruction. Nevertheless, a number of adverse events have been described, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Migration of covered stents [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/121\">",
"       121",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Failed deployment, impaction of the delivery device, dislodgement, migration, rupture [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/14,111,121,122\">",
"       14,111,121,122",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Early stent occlusion by blood clot [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/123\">",
"       123",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Duodenal ulceration, stent-related bleeding and perforation [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/124-128\">",
"       124-128",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Upper gastrointestinal bleeding from a biliary-duodenal fistula [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/129\">",
"       129",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hemobilia from a right hepatic artery pseudoaneurysm causing an arteriobiliary fistula in a patient with bile duct obstruction by lymphoma [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/130\">",
"       130",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Lower intestinal hemorrhage due to a dislodged metallic stent [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/131\">",
"       131",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Impaction of a plastic biliary stent placed through an occluded metal stent [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/132\">",
"       132",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Biliorenal fistula [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/133\">",
"       133",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Cholecystitis related to both uncovered and covered biliary stents [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/121,134\">",
"       121,134",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Fatal air embolism occurred following placement of metallic stent for an ampulloma [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/46\">",
"       46",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Massive hemobilia during extraction of a covered self-expandable metal stent in a patient with portal hypertension [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/135\">",
"       135",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A malpositioned metallic self-expandable stent penetrated the liver and extended into the peritoneal cavity [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/136\">",
"       136",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Guidewires",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidewire fracture during ERCP is rare. It has been reported in a few cases involving hydrophilic wires with an angled tip [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/137,138\">",
"     137,138",
"    </a>",
"    ], or following guidewire-assisted sphincterotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/12\">",
"     12",
"    </a>",
"    ]. Use of guide during ERCP was believed to cause an infected liver hematoma [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     GALLSTONE ILEUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large stones, usually over 25 mm, can cause gallstone ileus when released into the duodenum following endoscopic biliary sphincterotomy. The clinical presentation may be delayed by months, and be atypical or severe [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/139-141\">",
"     139-141",
"    </a>",
"    ]. Successful treatment by electrohydraulic lithotripsy and extracorporeal shock wave lithotripsy has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/142,143\">",
"     142,143",
"    </a>",
"    ]. However, the management is usually surgical [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/144\">",
"     144",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/62/26598?source=see_link\">",
"     \"Gallstone ileus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     RADIOLOGICAL MISDIAGNOSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications can arise from mistakes in the interpretation of diagnostic findings during ERCP. The most common mistake is missing common duct stones. Such patients may require subsequent investigations and have a delayed diagnosis resulting in potential insurance claims [",
"    <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/5,145,146\">",
"     5,145,146",
"    </a>",
"    ]. A more serious error is overlooking a hilar biliary stricture in a patient with biliary stones or erroneously considering a stricture to be benign.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     MISCELLANEOUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rare adverse events following ERCP continue to be reported including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Tooth injury",
"     </li>",
"     <li>",
"      Conjunctival ecchymosis",
"     </li>",
"     <li>",
"      Corneal abrasion [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/147\">",
"       147",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Uvular necrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/148\">",
"       148",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Transient swelling of the parotid gland (authors' personal observation) and acute parotitis [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/149\">",
"       149",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Dislocation of temporomandibular joint [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/150,151\">",
"       150,151",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hemolysis due to G-6-PD deficiency presumably induced by hypoxemia and temporary acidosis during ERCP with endoscopic sphincterotomy [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/152\">",
"       152",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Methemoglobinemia caused by topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/7/6264?source=see_link\">",
"       benzocaine",
"      </a>",
"      spray [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/153\">",
"       153",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/44/11976?source=see_link\">",
"       Meperidine (pethidine)",
"      </a>",
"      -induced hepatitis [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/154\">",
"       154",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hashimoto's thyroiditis presumed to be caused by contrast exposure [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/5\">",
"       5",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      An intramural duodenal hematoma [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/155,156\">",
"       155,156",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Mallory-Weiss tear [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/157\">",
"       157",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hepatic subcapsular biloma (a collection of bile outside the biliary tree) secondary to bile leak induced by high pressure injection of contrast [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/158\">",
"       158",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Pancreatic duct perforation during brushing [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/159\">",
"       159",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Prolonged cholestasis that may respond to glucocorticoids [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/160\">",
"       160",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Development of a pseudotumor of the pancreatic head after therapeutic ERCP [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/161\">",
"       161",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Duodenal obstruction following papillary stenosis [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/162\">",
"       162",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Electrical burn in the liver secondary to sphincterotomy [",
"      <a class=\"abstract\" href=\"UTD.htm?7/44/7882/abstract/163\">",
"       163",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4676219\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most frequent complications of endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic biliary sphincterotomy are pancreatitis, cholangitis, hemorrhage, and duodenal perforation. A number of less common adverse events have also been described. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/49/39705?source=see_link\">",
"       \"Overview of indications for and complications of ERCP and endoscopic biliary sphincterotomy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Some of the rare complications include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Severe respiratory and cardiac side effects. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Cardiopulmonary and sedation-related complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anaphylactic reactions to contrast agents used during ERCP. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Contrast allergy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Malfunction or incorrect use of electrosurgical equipment and accessories during therapeutic procedures, or defective devices can lead to potentially severe complications such as perforation, bleeding, and pancreatitis. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Electrosurgical hazards'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Opacification of the portal vein has been described with multiple therapeutic interventions. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Opacification of portal, arterial, or lymphatic vessels'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Appearance of gas in the portal venous system. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Portal vein gas, air, and bile embolism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cardiac and cerebral air embolism. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Portal vein gas, air, and bile embolism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intraperitoneal hemorrhage from injury to the spleen, liver, or abdominal vessels. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Hemorrhage from splenic, hepatic or vascular trauma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pneumothorax, pneumomediastinum, and pneumoperitoneum. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Pneumothorax, pneumomediastinum, and pneumoperitoneum'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Impaction of retrieval baskets and fracture of the traction wire. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Impaction of retrieval baskets and fracture of the traction wire'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications related to biliary and pancreatic stents. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Complications related to biliary and pancreatic stents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gallstone ileus due to the release of large stones, usually over 25 mm, into the duodenum. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Gallstone ileus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mistakes in the interpretation of diagnostic findings during ERCP.",
"      <strong>",
"      </strong>",
"      (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Radiological misdiagnoses'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/1\">",
"      Freeman ML, Nelson DB, Sherman S, et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996; 335:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/2\">",
"      Loperfido S, Angelini G, Benedetti G, et al. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. Gastrointest Endosc 1998; 48:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/3\">",
"      Masci E, Toti G, Mariani A, et al. Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. Am J Gastroenterol 2001; 96:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/4\">",
"      Andriulli A, Loperfido S, Napolitano G, et al. Incidence rates of post-ERCP complications: a systematic survey of prospective studies. Am J Gastroenterol 2007; 102:1781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/5\">",
"      Trap R, Adamsen S, Hart-Hansen O, Henriksen M. Severe and fatal complications after diagnostic and therapeutic ERCP: a prospective series of claims to insurance covering public hospitals. Endoscopy 1999; 31:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/6\">",
"      Arrowsmith JB, Gerstman BB, Fleischer DE, Benjamin SB. Results from the American Society for Gastrointestinal Endoscopy/U.S. Food and Drug Administration collaborative study on complication rates and drug use during gastrointestinal endoscopy. Gastrointest Endosc 1991; 37:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/7\">",
"      Michalodimitrakis M, Christodoulou P, Tsatsakis AM, et al. Death related to midazolam overdose during endoscopic retrograde cholangiopancreatography. Am J Forensic Med Pathol 1999; 20:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/8\">",
"      Fisher L, Fisher A, Thomson A. Cardiopulmonary complications of ERCP in older patients. Gastrointest Endosc 2006; 63:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/9\">",
"      Sharma VK, Nguyen CC, Crowell MD, et al. A national study of cardiopulmonary unplanned events after GI endoscopy. Gastrointest Endosc 2007; 66:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/10\">",
"      Draganov PV, Forsmark CE. Prospective evaluation of adverse reactions to iodine-containing contrast media after ERCP. Gastrointest Endosc 2008; 68:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/11\">",
"      Draganov P, Cotton PB. Iodinated contrast sensitivity in ERCP. Am J Gastroenterol 2000; 95:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/12\">",
"      Burdick JS, Schmalz MJ, Geenen JE. Guidewire fracture during endoscopic sphincterotomy. Endoscopy 1993; 25:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/13\">",
"      Johlin FC, Tucker RD, Ferguson S. The effect of guidewires during electrosurgical sphincterotomy. Gastrointest Endosc 1992; 38:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/14\">",
"      Ell C, Fleig WE, Hochberger J. Broken biliary metal stent after repeated electrocoagulation for tumor ingrowth. Gastrointest Endosc 1992; 38:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/15\">",
"      Petersen BT, Hussain N, Marine JE, et al. Endoscopy in patients with implanted electronic devices. Gastrointest Endosc 2007; 65:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/16\">",
"      Katsinelos P, Pilpilidis I, Paroutoglou G, et al. Pyogenic cholangitis after inadvertent submucosal contrast injection in the papilla of Vater in a patient with cholestatic hepatitis. Surg Endosc 2003; 17:1677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/17\">",
"      Huibregtse K, Gish R, Tytgat GN. A frightening event during endoscopic papillotomy. Gastrointest Endosc 1988; 34:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/18\">",
"      Ben-Zvi JS, Siegel JH, Yatto R. Opacification of the portal system during ERCP: demonstration of an anomalous pancreatico-portal connection in a patient with pancreatic carcinoma. Gastrointest Endosc 1989; 35:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/19\">",
"      Siegel JH, Ben-Zvi JS, Yatto RP. Portal vein filling during ERCP. Gastrointest Endosc 1993; 39:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/20\">",
"      Ricci E, Mortilla MG, Conigliaro R, et al. Portal vein filling: a rare complication associated with ERCP for endoscopic biliary stent placement. Gastrointest Endosc 1992; 38:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/21\">",
"      Espinel J, Pinedo ME, Calleja JL. Portal vein filling: an unusual complication of needle-knife sphincterotomy. Endoscopy 2007; 39 Suppl 1:E245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/22\">",
"      Cotton PB. Portal vein filling during ERCP. Gastrointest Endosc 1994; 40:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/23\">",
"      Lum C, Cho KC, Scholl DG, Sundaram NK. Portal vein opacification during ERCP in patients with pancreatitis. Abdom Imaging 1998; 23:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/24\">",
"      Gottschalk U, Morgenstern C, Kadow K. [Accidental cannulation of the hepatic artery following needle-knife sphincterotomy]. Z Gastroenterol 2007; 45:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/25\">",
"      Dickey W, Huibregtse K, Rauws EA, Tytgat GN. Direct pancreatic lymphangiography during ERCP. Gastrointest Endosc 1995; 41:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/26\">",
"      Furuzono M, Hirata N, Saitou J, Nakaji S. A rare complication during ERCP and sphincterotomy: placement of an endoscopic nasobiliary drainage tube in the portal vein. Gastrointest Endosc 2009; 70:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/27\">",
"      Stableforth WD, Pathmakanthan S, Holt A, et al. Iatrogenic portobiliary fistula complicating endoscopic stenting of a pancreatic cyst, with possible carcinoma: a case report. Gastrointest Endosc 2011; 73:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/28\">",
"      Sezgin O, Tezel A, Sahin B. Limited duodenal pneumatosis during needle-knife sphincterotomy. Endoscopy 1999; 31:S54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/29\">",
"      Simmons TC. Hepatic portal venous gas due to endoscopic sphincterotomy. Am J Gastroenterol 1988; 83:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/30\">",
"      Herman JB, Levine MS, Long WB. Portal venous gas as a complication of ERCP and endoscopic sphincterotomy. Am J Gastroenterol 1995; 90:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/31\">",
"      Blind PJ, Oberg L, Hedberg B. Hepatic portal vein gas following endoscopic retrograde cholangiography with sphincterotomy. Case report. Eur J Surg 1991; 157:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/32\">",
"      Barthet M, Membrini P, Bernard JP, Sahel J. Hepatic portal venous gas after endoscopic biliary sphincterotomy. Gastrointest Endosc 1994; 40:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/33\">",
"      Merine D, Fishman EK. Uncomplicated portal venous gas associated with duodenal perforation following ERCP: CT features. J Comput Assist Tomogr 1989; 13:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/34\">",
"      Tighe M, Jacobson I. Bleeding from bile duct varices: an unexpected hazard during therapeutic ERCP. Gastrointest Endosc 1996; 43:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/35\">",
"      Kennedy C, Larvin M, Linsell J. Fatal hepatic air embolism following ERCP. Gastrointest Endosc 1997; 45:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/36\">",
"      Siddiqui J, Jaffe PE, Aziz K, et al. Fatal air and bile embolism after percutaneous liver biopsy and ERCP. Gastrointest Endosc 2005; 61:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/37\">",
"      Rabe C, Balta Z, W&uuml;llner U, et al. Biliary metal stents and air embolism: a note of caution. Endoscopy 2006; 38:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/38\">",
"      Cha ST, Kwon CI, Seon HG, et al. Fatal biliary-systemic air embolism during endoscopic retrograde cholangiopancreatography: a case with multifocal liver abscesses and choledochoduodenostomy. Yonsei Med J 2010; 51:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/39\">",
"      Finsterer J, St&ouml;llberger C, Bastovansky A. Cardiac and cerebral air embolism from endoscopic retrograde cholangio-pancreatography. Eur J Gastroenterol Hepatol 2010; 22:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/40\">",
"      Mohammedi I, Ber C, Peguet O, et al. Cardiac air embolism after endoscopic retrograde cholangiopancreatography in a patient with blunt hepatic trauma. J Trauma 2002; 53:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/41\">",
"      Giuly E, Pesenti C, Pernoud N, et al. [Air embolism: an unusual complication of endoscopic retrograde cholangiopancreatography]. Ann Fr Anesth Reanim 2005; 24:1400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/42\">",
"      Romberg C. Systemic air embolism after ERCP: a case report and review of the literature (with video). Gastrointest Endosc 2009; 70:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/43\">",
"      Goins KM, May JM, Hucklenbruch C, et al. Unexpected cardiovascular collapse from massive air embolism during endoscopic retrograde cholangiopancreatography. Acta Anaesthesiol Scand 2010; 54:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/44\">",
"      Nayagam J, Ho KM, Liang J. Fatal systemic air embolism during endoscopic retrograde cholangio-pancreatography. Anaesth Intensive Care 2004; 32:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/45\">",
"      Stabile L, Cigada M, Stillittano D, et al. Fatal cerebral air embolism after endoscopic retrograde cholangiopancreatography. Acta Anaesthesiol Scand 2006; 50:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/46\">",
"      Tan BK, Saunier CF, Cotton F, et al. [Thoracoabdominal CT scan: a useful tool for the diagnosis of air embolism during an endoscopic retrograde cholangiopancreatography]. Ann Fr Anesth Reanim 2008; 27:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/47\">",
"      Rangappa P, Uhde B, Byard RW, et al. Fatal cerebral arterial gas embolism after endoscopic retrograde cholangiopancreatography. Indian J Crit Care Med 2009; 13:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/48\">",
"      Arg&uuml;elles Garcia B, Garcia Blanco A, Meilan Martinez A, et al. Cerebral artery air embolism secondary to endoscopic retrograde cholangiopancreatography. Gastroenterol Hepatol Spanish 2009; 32:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/49\">",
"      van Boxel GI, Hommers CE, Dash I, et al. Myocardial and cerebral infarction due to massive air embolism following endoscopic retrograde cholangiopancreatography (ERCP). Endoscopy 2010; 42 Suppl 2:E80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/50\">",
"      Albert JG, Friedrich-Rust M, Elhendawy M, et al. Peroral cholangioscopy for diagnosis and therapy of biliary tract disease using an ultra-slim gastroscope. Endoscopy 2011; 43:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/51\">",
"      Bisceglia M, Simeone A, Forlano R, et al. Fatal systemic venous air embolism during endoscopic retrograde cholangiopancreatography. Adv Anat Pathol 2009; 16:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/52\">",
"      Mal F, Choury AD, De Castro V, et al. [Fatal venous air embolism during biliary endoscopy]. Gastroenterol Clin Biol 2010; 34:e17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/53\">",
"      Di Pisa M, Chiaramonte G, Arcadipane A, et al. Air embolism during endoscopic retrograde cholangiopancreatography in a pediatric patient. Minerva Anestesiol 2011; 77:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/54\">",
"      Jow AZ, Wan D. Complication of cardiac air embolism during ERCP and EUS-assisted cyst-gastrostomy for pancreatic pseudocyst. Gastrointest Endosc 2012; 75:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/55\">",
"      Bechi A, Nucera MP, Olivotto I, et al. Complete neurological recovery after systemic air embolism during endoscopic retrograde cholangiopancreatography. Minerva Anestesiol 2012; 78:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/56\">",
"      Maccarone G, Shakoor T, Ellis B. Air embolism after percutaneous transhepatic biliary drainage and subsequent endoscopic retrograde cholangiopancreatography (ERCP). Endoscopy 2011; 43 Suppl 2 UCTN:E399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/57\">",
"      Koehler LS, Christides PS, Adamec TA. A complication of percutaneous cholangiography resulting in hypoxia and death of an anesthetized patient. Anesthesiology 1978; 49:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/58\">",
"      Armellin GM, Smith RC, Faithfull GR. Pulmonary bile emboli following percutaneous cholangiography and biliary drainage. Pathology 1981; 13:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/59\">",
"      Wu WC, Katon RM. Injury to the liver and spleen after diagnostic ERCP. Gastrointest Endosc 1993; 39:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/60\">",
"      Lo AY, Washington M, Fischer MG. Splenic trauma following endoscopic retrograde cholangiopancreatography (ERCP). Surg Endosc 1994; 8:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/61\">",
"      Risher WH, Smith JW. Intraperitoneal hemorrhage from injury to the gastroepiploic artery: a complication of endoscopic retrograde sphincterotomy. Gastrointest Endosc 1990; 36:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/62\">",
"      Milanchi S, Magner D, Lo SK, et al. Abdominal compartment syndrome secondary to retroperitoneal hematoma as a complication of ERCP after liver transplantation. Transplant Proc 2007; 39:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/63\">",
"      Kingsley DD, Schermer CR, Jamal MM. Rare complications of endoscopic retrograde cholangiopancreatography: two case reports. JSLS 2001; 5:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/64\">",
"      Poon CM, Lee FY, Ko CW, et al. A rare complication of intra-abdominal hematoma after ERCP. Gastrointest Endosc 2002; 56:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/65\">",
"      Orlando G, Bellini P, Borioni R, Pace A. Laparoscopic cholecystectomy and the Peter Pan syndrome. Surg Endosc 2000; 14:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/66\">",
"      C&aacute;rdenas A, Crespo G, Balderramo D, et al. Subcapsular liver hematoma after Endoscopic Retrograde Cholangiopancreatography in a liver transplant recipient. Ann Hepatol 2008; 7:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/67\">",
"      McArthur KS, Mills PR. Subcapsular hepatic hematoma after ERCP. Gastrointest Endosc 2008; 67:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/68\">",
"      Costa Macedo T, Maldonado R, Valente A, et al. Hemobilia in hereditary hemorrhagic telangiectasia: an unusual complication of endoscopic retrograde cholangiopancreatography. Endoscopy 2003; 35:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/69\">",
"      Gholson CF, Williams C, Patterson CR. Bloody drainage following endoscopic retrograde pancreatography as a presentation of a pseudoaneurysm-containing pseudocyst. Gastrointest Endosc 1989; 35:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/70\">",
"      al-Jeroudi A, Belli AM, Shorvon PJ. False aneurysm of the pancreaticoduodenal artery complicating therapeutic endoscopic retrograde cholangiopancreatography. Br J Radiol 2001; 74:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/71\">",
"      Austin AS, Lobo DN, Hinwood D, et al. Intra-hepatic false aneurysm: a rare complication of ERCP. Eur J Gastroenterol Hepatol 1999; 11:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/72\">",
"      Pohle T, Domschke W, Lerch MM. Needle knife precut-induced bleeding from a \"pancreatic cyst\". Gastrointest Endosc 2000; 52:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/73\">",
"      Mosenkis BN, Brandt LJ. Bleeding causing biliary obstruction after endoscopic sphincterotomy. Am J Gastroenterol 1997; 92:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/74\">",
"      Ala A, Khin CC, van Someren N. Common bile duct thrombus: a cause of persisting obstructive jaundice after endoscopic sphincterotomy. Gastrointest Endosc 1999; 50:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/75\">",
"      Chochon M, Colardelle P, Choury D, et al. [Cholangitis induced by an obstructive blood clot after endoscopic sphincterotomy]. Gastroenterol Clin Biol 1994; 18:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/76\">",
"      Heller AM, Hohl R, Madhavan T, Wong K. Retropharyngeal abscess after endoscopic retrograde cholangiopancreatography: an uncommon but potentially fatal complication. South Med J 1978; 71:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/77\">",
"      Riahi S, Hansen J, Bjerre J, Kragsbjerg P. ERCP complicated by a retroperitoneal abscess caused by Haemophilus influenzae and Haemophilus parainfluenzae. Gastrointest Endosc 1998; 47:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/78\">",
"      Furman G, Morgenstern L. Splenic injury and abscess complicating endoscopic retrograde cholangiopancreatography. Surg Endosc 1993; 7:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/79\">",
"      Gilad J, David A, Hertzanu Y, et al. Endoscopic biliary sphincterotomy complicated by abscess formation in a simple renal cyst. Endoscopy 1999; 31:S5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/80\">",
"      Hendlisz A, Rypens F, Gay F, et al. Spinal epidural abscess after endoscopic treatment for chronic pancreatitis. Pancreas 1995; 10:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/81\">",
"      Tooson JD, Alexander GL, Batts KP. Perforation of the sigmoid colon after therapeutic UGI endoscopy. Gastrointest Endosc 1995; 41:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/82\">",
"      Manbeck MA, Chang AC, McCracken JD, Chen YK. Cystic duct perforation as a complication of endoscopic stone extraction. Am J Gastroenterol 1996; 91:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/83\">",
"      Borgharia S, Jindal V, Gautam V, et al. Subcutaneous emphysema of the penis and scrotum mimicking gas gangrene: a rare complication of ERCP. Gastrointest Endosc 2011; 73:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/84\">",
"      Rai A, Iftikhar S. Tension pneumothorax complicating diagnostic upper endoscopy: a case report. Am J Gastroenterol 1999; 94:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/85\">",
"      Minocha A, Richards RJ. Pneumothorax complicating diagnostic upper endoscopy. Am J Gastroenterol 1999; 94:2323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/86\">",
"      Morley AP, Lau JY, Young RJ. Tension pneumothorax complicating a perforation of a duodenal ulcer during ERCP with endoscopic sphincterotomy. Endoscopy 1997; 29:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/87\">",
"      Han ML, Wu YM, Liu KL, et al. Tension pneumothorax after an ERCP in a patient with hepatic hydrothorax and sealed-off perforated duodenal ulcer. Gastrointest Endosc 2008; 68:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/88\">",
"      Ciaccia D, Branch MS, Baillie J. Pneumomediastinum after endoscopic sphincterotomy. Am J Gastroenterol 1995; 90:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/89\">",
"      Markogiannakis H, Toutouzas KG, Pararas NV, et al. Bilateral pneumothorax following endoscopic retrograde cholangiopancreatography: a case report. Endoscopy 2007; 39 Suppl 1:E195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/90\">",
"      Bar-Meir S, Lang A, Shemesh E, et al. Pneumoperitoneum after insertion of endoscopic biliary stent for post-cholecystectomy biliary leak. Gastrointest Endosc 1993; 39:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/91\">",
"      Assimakopoulos SF, Thomopoulos KC, Giali S, et al. A rare etiology of post-endoscopic retrograde cholangiopancreatography pneumoperitoneum. World J Gastroenterol 2008; 14:2917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/92\">",
"      Sheridan J, Williams TM, Yeung E, et al. Percutaneous transhepatic management of an impacted endoscopic basket. Gastrointest Endosc 1993; 39:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/93\">",
"      Cutler AF, Hassig WM, Schubert TT. Basket impaction at the pancreatic head. Gastrointest Endosc 1992; 38:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/94\">",
"      Mutignani M, Gabbrielli A, Murali N, et al. Novel methods of management of trapped dormia baskets in the pancreatic and biliary ducts. Endoscopy 1997; 29:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/95\">",
"      Ng WT, Yiu MK, Lee K. Impaction of a stone basket in the gallbladder with laparoscopic rescue. Gastrointest Endosc 1993; 39:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/96\">",
"      Somogyi L, Chuttani R, Croffie J, et al. Biliary and pancreatic stents. Gastrointest Endosc 2006; 63:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/97\">",
"      Nicholson AA, Martin DF. Misplacement of endoscopic biliary endoprostheses. Endoscopy 1997; 29:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/98\">",
"      Ang BK, Wee SB, Kaushik SP, Low CH. Duodenal-colic fistula resulting from migration of a biliary stent: a case report. Gastrointest Endosc 1998; 48:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/99\">",
"      Ros&eacute;s LL, Ramirez AG, Seco AL, et al. Clip closure of a duodenal perforation secondary to a biliary stent. Gastrointest Endosc 2000; 51:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/100\">",
"      Christensen M, Matzen P, Schulze S, Rosenberg J. Complications of ERCP: a prospective study. Gastrointest Endosc 2004; 60:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/101\">",
"      S&aacute;nchez-Tembleque MD, Naranjo Rodr&iacute;guez A, Ruiz Morales R, et al. [Duodenal perforation due to an endoscopic biliary prosthesis]. Gastroenterol Hepatol 2005; 28:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/102\">",
"      Amann ST, Somogyi L. A wire-loop technique for removal of migrated and embedded biliary stents. Gastrointest Endosc 2000; 51:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/103\">",
"      Paikos D, Gatopoulou A, Moschos J, et al. Migrated biliary stent predisposing to fatal ERCP-related perforation of the duodenum. J Gastrointestin Liver Dis 2006; 15:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/104\">",
"      Distefano M, Bonanno G, Russo A. Biliocutaneous fistula following biliary stent migration. Endoscopy 2001; 33:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/105\">",
"      Basile A, Macri' A, Lamberto S, et al. Duodenoscrotal fistula secondary to retroperitoneal migration of an endoscopically placed plastic biliary stent. Gastrointest Endosc 2003; 57:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/106\">",
"      St&oslash;rkson RH, Edwin B, Reiertsen O, et al. Gut perforation caused by biliary endoprosthesis. Endoscopy 2000; 32:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/107\">",
"      Ruinemans GM, van Zanten RA, Rakic S, et al. [Abdominal pain following placement of an endoprosthesis in the biliary duct]. Ned Tijdschr Geneeskd 2006; 150:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/108\">",
"      Wilhelm A, Langer C, Zoeller G, et al. Complex colovesicular fistula: A severe complication caused by biliary stent migration. Gastrointest Endosc 2003; 57:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/109\">",
"      Wagemakers S, Ibelings M. [Colovesicular fistula after migration of a biliary stent]. Ned Tijdschr Geneeskd 2011; 155:A3615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/110\">",
"      Johanson JF, Schmalz MJ, Geenen JE. Incidence and risk factors for biliary and pancreatic stent migration. Gastrointest Endosc 1992; 38:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/111\">",
"      Diller R, Senninger N, Kautz G, T&uuml;bergen D. Stent migration necessitating surgical intervention. Surg Endosc 2003; 17:1803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/112\">",
"      Lahoti S, Catalano MF, Geenen JE, Schmalz MJ. Endoscopic retrieval of proximally migrated biliary and pancreatic stents: experience of a large referral center. Gastrointest Endosc 1998; 47:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/113\">",
"      Chaurasia OP, Rauws EA, Fockens P, Huibregtse K. Endoscopic techniques for retrieval of proximally migrated biliary stents: the Amsterdam experience. Gastrointest Endosc 1999; 50:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/114\">",
"      Kawakami H, Uebayashi M, Konishi K, et al. A rare complication with extraction of proximally migrated biliary stent by using a basket catheter. Gastrointest Endosc 2008; 67:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/115\">",
"      Elewaut A, De Vos M, Huble F, De Cock J. Unusual migration of a straight Amsterdam-type endoprosthesis for bile duct stones. Am J Gastroenterol 1989; 84:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/116\">",
"      Heyries L, Desjeux A, Sahel J. Bile duct-duodenum and pancreatic-gastric fistulas: two exceptional complications of biliary and pancreatic stenting. Gastrointest Endosc 1999; 50:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/117\">",
"      Richenberg JI, Amin Z, Hatfield AR, Lees WR. Pleurobiliary fistula following Tannenbaum biliary stent insertion. Eur Radiol 1996; 6:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/118\">",
"      Mahadeva S, Ranjeev P, Goh KL. Hepaticogastric fistulation from a proximally migrated biliary stent. Gastrointest Endosc 2003; 58:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/119\">",
"      Tung BY, Kowdley KV, Kimmey MB. Pancreatic fistula without pancreatitis after endoscopic biliary stent placement for bile leak after orthotopic liver transplantation. Gastrointest Endosc 1999; 49:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/120\">",
"      Vimalraj V, Jeswanth S, Kannan DG, et al. Acute portal vein thrombosis and massive necrosis of the liver. An unusual complication after stenting for chronic pancreatitis. JOP 2006; 7:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/121\">",
"      Kahaleh M, Tokar J, Conaway MR, et al. Efficacy and complications of covered Wallstents in malignant distal biliary obstruction. Gastrointest Endosc 2005; 61:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/122\">",
"      Born P, R&ouml;sch T, Classen M. Spontaneous rupture of a biliary metal stent. Endoscopy 1998; 30:S78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/123\">",
"      Baron TH. Hemobilia-induced occlusion of a biliary metal expandable stent. Gastrointest Endosc 2001; 54:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/124\">",
"      Ee H, Laurence BH. Haemorrhage due to erosion of a metal biliary stent through the duodenal wall. Endoscopy 1992; 24:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/125\">",
"      Marano BJ Jr, Bonanno CA. Metallic biliary endoprosthesis causing duodenal perforation and acute upper gastrointestinal bleeding. Gastrointest Endosc 1994; 40:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/126\">",
"      Cvetkovski B, Kurtz RC. Hemobilia in advanced pancreatic cancer with portal vein obstruction and a metal endobiliary stent: a case report. Gastrointest Endosc 1999; 50:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/127\">",
"      Gardiner MF, Long WB, Haskal ZJ, Lichtenstein GR. Upper gastrointestinal hemorrhage secondary to erosion of a biliary Wallstent in a woman with pancreatic cancer. Endoscopy 2000; 32:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/128\">",
"      Dokas S, Kotsis V, Milionis G, et al. Fatal upper gastrointestinal bleeding caused by a metal biliary stent despite stent shortening with APC. Endoscopy 2008; 40 Suppl 2:E135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/129\">",
"      Hyun CB, Bemiller T. Biliary-duodenal fistula caused by metal stent. Gastrointest Endosc 2001; 54:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/130\">",
"      Rai R, Rose J, Manas D. Potentially fatal haemobilia due to inappropriate use of an expanding biliary stent. World J Gastroenterol 2003; 9:2377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/131\">",
"      Wong SY, Ng FH. Lower intestinal hemorrhage due to a dislodged metallic stent. Endoscopy 1997; 29:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/132\">",
"      Jones WF, Harford W, Goldschmiedt M. Removal of plastic biliary stents placed through metal stent. Gastrointest Endosc 1993; 39:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/133\">",
"      Vila JJ, Jim&eacute;nez FJ, Irisarri R, et al. Biliorenous fistula related to self-expandable biliary metallic stent placement: a rare complication of endoscopic retrograde cholangiopancreatography. Endoscopy 2007; 39 Suppl 1:E67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/134\">",
"      Isayama H, Kawabe T, Nakai Y, et al. Cholecystitis after metallic stent placement in patients with malignant distal biliary obstruction. Clin Gastroenterol Hepatol 2006; 4:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/135\">",
"      Layec S, D'Halluin PN, Pagenault M, Bretagne JF. Massive hemobilia during extraction of a covered self-expandable metal stent in a patient with portal hypertensive biliopathy. Gastrointest Endosc 2009; 70:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/136\">",
"      Akaraviputh T, Iramaneerat C, Trakarnsanga A. Liver injury from endoscopic insertion of self-expandable metallic stent to relieve biliary obstruction: a fatal complication. Gastrointest Endosc 2009; 70:554; discussion 555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/137\">",
"      Pruitt A, Schutz SM, Baron T, et al. Fractured hydrophilic guidewire during ERCP: a case series. Gastrointest Endosc 1998; 48:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/138\">",
"      Heinerman M, Mann R, Boeckl O. An unusual complication in attempted non-surgical treatment of pancreatic bile duct stones. Endoscopy 1993; 25:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/139\">",
"      Williams IM, Hughes OD, Hicks E, Lewis MH. Gall stone ileus following multiple endoscopic retrograde cholangiopancreatographies. J R Coll Surg Edinb 1997; 42:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/140\">",
"      Oskam J, Heitbrink M, Eeftinck Schattenkerk M. Intermittent gallstone ileus following endoscopic biliary sphincterotomy. A case report. Acta Chir Belg 1993; 93:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/141\">",
"      Welch NT, Ellis DJ, Bradby GV. Necrotizing fasciitis--a complication of \"successful\" endoscopic sphincterotomy. Gastrointest Endosc 1990; 36:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/142\">",
"      Meyenberger C, Michel C, Metzger U, Koelz HR. Gallstone ileus treated by extracorporeal shockwave lithotripsy. Gastrointest Endosc 1996; 43:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/143\">",
"      Bourke MJ, Schneider DM, Haber GB. Electrohydraulic lithotripsy of a gallstone causing gallstone ileus. Gastrointest Endosc 1997; 45:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/144\">",
"      Sivagnanam P, Cheong E, Rhodes M. Delayed gallstone ileus presentation after ERCP and sphincterotomy. Gastrointest Endosc 2009; 69:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/145\">",
"      Chan CK, Pace RF. Misdiagnosis using endoscopic retrograde cholangiopancreatography in a patient with postcholecystectomy pain. Surg Endosc 1987; 1:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/146\">",
"      Meier R, Jubin E, Gyr K. [Missed gallstones in endoscopic retrograde cholangiopancreatography (ERCP). Case reports]. Schweiz Rundsch Med Prax 1988; 77:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/147\">",
"      Green JA, Goldman JH, Bernstein D, Barkin JS. Corneal abrasion occurring during ERCP. Gastrointest Endosc 1994; 40:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/148\">",
"      Gupte AR, Draganov PV. Post-endoscopic retrograde cholangiopancreatography uvular necrosis. Clin Gastroenterol Hepatol 2009; 7:A18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/149\">",
"      Nadkarni N, D'Cruz S, Kaur N, Sachdev A. Acute parotitis after ERCP. Gastrointest Endosc 2011; 74:199; discussion 199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/150\">",
"      Schlidt R, Marsh W, Schorr S. Pseudo stroke after an ERCP. Gastrointest Endosc 1994; 40:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/151\">",
"      To EW, Pang PC, Lee DW. Temporomandibular joint dislocation during endoscopic retrograde cholangiopancreatography examination. Endoscopy 2000; 32:S36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/152\">",
"      Katsinelos P, Paroutoglou G, Pilpilidis I, et al. Hemolysis caused by G-6PD deficiency after a difficult and prolonged therapeutic endoscopic retrograde cholangiopancreatography. Surg Endosc 2003; 17:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/153\">",
"      Guerriero SE. Methemoglobinemia caused by topical benzocaine. Pharmacotherapy 1997; 17:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/154\">",
"      Kluender CN, Klein R, Kohler B. Dramatic increase in bilirubin after ERCP - pethidine as a possible cause of drug-induced hepatitis. Z Gastroenterol 2003; 41:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/155\">",
"      Patel R, Shaps J. Intramural duodenal hematoma--a complication of ERCP. Gastrointest Endosc 1982; 28:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/156\">",
"      Sisley JF, Bowden TA, Mansberger AR Jr. Pancreatic duct disruption and duodenal hematoma associated with endoscopic retrograde cholangiopancreatography. South Med J 1987; 80:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/157\">",
"      Scium&egrave; C, Geraci G, Pisello F, et al. [A rare complication of ERCP: Mallory-Weiss syndrome]. Ann Ital Chir 2005; 76:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/158\">",
"      Dupas JL, Mancheron H, Sevenet F, et al. Hepatic subcapsular biloma. An unusual complication of endoscopic retrograde cholangiopancreatography. Gastroenterology 1988; 94:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/159\">",
"      Sonoda Y, Kobayashi K, Kawamoto M, et al. Inadvertent pancreatic duct perforation during brushing. Gastrointest Endosc 2003; 58:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/160\">",
"      Dourakis SP, Mayroyannis C, Alexopoulou A, Hadziyannis SJ. Prolonged cholestatic jaundice after endoscopic retrograde cholangiography. Hepatogastroenterology 1997; 44:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/161\">",
"      de Vries JH, Duijm LE, Dekker W, et al. CT before and after ERCP: detection of pancreatic pseudotumor, asymptomatic retroperitoneal perforation, and duodenal diverticulum. Gastrointest Endosc 1997; 45:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/162\">",
"      Lim JU, Joo KR, Park JJ, et al. Duodenal obstruction following papillary stenosis: a rare complication after endoscopic sphincterotomy. Endoscopy 2010; 42 Suppl 2:E342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/44/7882/abstract/163\">",
"      Kantarci M, Doganay S, Yalcin A, Cankaya B. Unusual complications during endoscopic retrograde cholangiopancreatography (ERCP): Electrical burn in the liver. Gastroenterol Clin Biol 2011.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 638 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-1D72A0B336-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_44_7882=[""].join("\n");
var outline_f7_44_7882=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4676219\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CARDIOPULMONARY AND SEDATION-RELATED COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CONTRAST ALLERGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ELECTROSURGICAL HAZARDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EXTRAVASATION OF CONTRAST MEDIUM INTO THE DUODENAL WALL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      OPACIFICATION OF PORTAL, ARTERIAL, OR LYMPHATIC VESSELS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DUODENAL PNEUMATOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PORTAL VEIN GAS, AIR, AND BILE EMBOLISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      HEMORRHAGE FROM SPLENIC, HEPATIC OR VASCULAR TRAUMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      RARE SEPTIC COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      RARE PERFORATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PNEUMOTHORAX, PNEUMOMEDIASTINUM, AND PNEUMOPERITONEUM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      IMPACTION OF RETRIEVAL BASKETS AND FRACTURE OF THE TRACTION WIRE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      COMPLICATIONS RELATED TO BILIARY AND PANCREATIC STENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Plastic biliary and pancreatic stents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Metal stents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Guidewires",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      GALLSTONE ILEUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      RADIOLOGICAL MISDIAGNOSES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      MISCELLANEOUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4676219\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/638\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/638|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/60/40911\" title=\"table 1\">",
"      Air embolism during ERCP",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22905?source=related_link\">",
"      Endoscopic management of bile duct stones: Standard techniques and mechanical lithotripsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/62/26598?source=related_link\">",
"      Gallstone ileus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/49/39705?source=related_link\">",
"      Overview of indications for and complications of ERCP and endoscopic biliary sphincterotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42072?source=related_link\">",
"      Overview of pancreatic stenting and its complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26216?source=related_link\">",
"      Post-ERCP bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/38/20072?source=related_link\">",
"      Post-ERCP perforation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23959?source=related_link\">",
"      Post-ERCP septic complications",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_44_7883="Clinical features of Adies syndrome";
var content_f7_44_7883=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F57952&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F57952&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical features of Adie's syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent prevalence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unilateral",
"       </td>",
"       <td>",
"        80*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reduced deep tendon reflexes",
"       </td>",
"       <td>",
"        89",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sector palsy (if residual light reaction)",
"       </td>",
"       <td>",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Accommodative paresis",
"       </td>",
"       <td>",
"        66",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cholinergic supersensitivity",
"       </td>",
"       <td>",
"        80",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased regional corneal sensation",
"       </td>",
"       <td>",
"        90",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * 4 percent per year will become bilateral.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Thompson, HS. Adie's syndrome: Some new observations. Trans Am Ophthalmol Soc 1977; 75:587. Copyright &copy; 1977 American Ophthalmalogic Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_44_7883=[""].join("\n");
var outline_f7_44_7883=null;
var title_f7_44_7884="Suicide resources B";
var content_f7_44_7884=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Suicide resources (continued)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"       In an emergency, call 1-800-SUICIDE (1-800-784-2433), the national suicide hotline.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"1\">",
"       <p>",
"        National Mental Health Association (NMHA)",
"       </p>",
"       <p>",
"        www.nmha.org",
"       </p>",
"       <p>",
"        800-228-1114",
"       </p>",
"       <p>",
"        800-969-NMHA (6642)",
"       </p>",
"       <p>",
"        800-433-5959 (TTY)",
"       </p>",
"      </td>",
"      <td>",
"       Provides information on depression and its treatment and referrals to local screening sites.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"1\">",
"       <p>",
"        The National Mental Illness Screening Project Suicide Division",
"       </p>",
"       <p>",
"        www.nmisp.org",
"       </p>",
"       <p>",
"        800-573-4433",
"       </p>",
"      </td>",
"      <td>",
"       Provides information regarding free, confidential screening near you.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"1\">",
"       <p>",
"        Suicide Awareness-Voices of Education (SA\VE)",
"       </p>",
"       <p>",
"        www.save.org",
"       </p>",
"       <p>",
"        612-946-7998",
"       </p>",
"      </td>",
"      <td colspan=\"1\">",
"       Provides suicide education, facts, and statistics on suicide and depression. It links to information on warning signs of suicide and the role a friend or family member can play in helping a suicidal person.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"1\">",
"       <p>",
"        Suicide Information &amp; Education Centre (SIEC)",
"       </p>",
"       <p>",
"        www.siec.ca",
"       </p>",
"       <p>",
"        403-245-3900",
"       </p>",
"      </td>",
"      <td colspan=\"1\">",
"       Library and resource center providing information on suicide and suicidal behavior.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"1\">",
"       <p>",
"        Suicide Prevention Advocacy Network (SPAN)",
"       </p>",
"       <p>",
"        spanusa.org",
"       </p>",
"       <p>",
"        888-649-1366",
"       </p>",
"       <p>",
"        Substance Abuse and Mental Health Administration (SAMHSA) www.samhsa.gov",
"       </p>",
"      </td>",
"      <td colspan=\"1\">",
"       SPAN is a nonprofit organization dedicated to creating an effective national suicide prevention strategy. SPAN links the energy of those bereaved by suicide with the expertise of leaders in science, business, government, and public service to achieve the goal of significantly reducing the national suicide rate by the year 2010.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: www.cdc.gov/ncipc/dvp/youth/suicide.htm and www.cdc.gov/safeusa/suicide.htm#Safety%20Resources.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_44_7884=[""].join("\n");
var outline_f7_44_7884=null;
var title_f7_44_7885="Respiratory disease from RA drugs";
var content_f7_44_7885=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F65141&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F65141&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pulmonary complications from drugs for rheumatoid arthritis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pneumonitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methotrexate*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gold*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leflunomide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        d-Penicillamine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TNF inhibitors",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        NSAID",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyclophosphamide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Azathioprine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sulfasalazine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chlorambucil",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methotrexate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gold",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyclophosphamide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chlorambucil",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Azathioprine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sulfasalazine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Obliterative bronchiolitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        d-Pencillamine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gold",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sulfasalazine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TNF inhibitors",
"        <sup>",
"         &Delta;",
"        </sup>",
"        *",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IL-1 inhibitors",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methotrexate*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glucocorticoids*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyclophosphamide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Noncardiogenic pulmonary edema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aspirin (high doses)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        NSAID",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methotrexate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyclophosphamide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colchicine (overdose)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pulmonary renal syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pulmonary hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        d-Penicillamine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Drug-induced lupus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        d-Penicillamine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TNF inhibitors",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sulfasalazine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Bronchospasm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aspirin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        NSAID",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methotrexate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Air trapping",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ? Methotrexate",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Most common reactions reported.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Nonsteroidal anti-inflammatory medications.",
"     <br/>",
"     &Delta; Tumor necrosis factor modifying agents (infliximab, etanercept, adalimumab).",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Interleukin-1 blocking agents (anakinra).",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_44_7885=[""].join("\n");
var outline_f7_44_7885=null;
var title_f7_44_7886="Reports XDR TB rx outcomes";
var content_f7_44_7886=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F51301&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F51301&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Reports of XDR* TB treatment and outcomes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Study",
"        <span class=\"small\">",
"         &bull;",
"        </span>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Time period",
"       </td>",
"       <td class=\"subtitle1\">",
"        Region/population",
"       </td>",
"       <td class=\"subtitle1\">",
"        Treatment regimen",
"       </td>",
"       <td class=\"subtitle1\">",
"        Outcome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shah et al.",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td>",
"        1993-2007",
"       </td>",
"       <td>",
"        <p>",
"         United States, all reported cases",
"        </p>",
"        <p>",
"         n = 83",
"        </p>",
"        <p>",
"         31 (37 percent) HIV positive",
"        </p>",
"       </td>",
"       <td>",
"        Not reported",
"       </td>",
"       <td>",
"        <p>",
"         26 (35 percent) died",
"        </p>",
"        <p>",
"         21 (81 percent) deaths were HIV positive",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Banerjee et al.&Delta;",
"       </td>",
"       <td>",
"        1993-2006",
"       </td>",
"       <td>",
"        <p>",
"         All cases reported in California",
"        </p>",
"        <p>",
"         n = 18",
"        </p>",
"        <p>",
"         All HIV negative",
"        </p>",
"       </td>",
"       <td>",
"        Not reported",
"       </td>",
"       <td>",
"        <p>",
"         17 known outcomes",
"        </p>",
"        <p>",
"         10 (59 percent) treatment failures",
"        </p>",
"        <p>",
"         5 (29 percent) died",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kim et al.",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"       <td>",
"        1996-2005",
"       </td>",
"       <td>",
"        <p>",
"         Seoul, South Korea",
"        </p>",
"        <p>",
"         Referral hospital",
"        </p>",
"        <p>",
"         n = 43",
"        </p>",
"        <p>",
"         All HIV negative",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Individualized based on DST",
"        </p>",
"        <p>",
"         Use any susceptible first-line meds",
"        </p>",
"        <p>",
"         Supplement with second-line agents to reach 5 drugs",
"        </p>",
"        <p>",
"         Treatment duration: two years after culture conversion",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         19 (44 percent) treatment failures",
"        </p>",
"        <p>",
"         6 (14 percent) died",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mitnick et al.",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"       <td>",
"        1999-2002",
"       </td>",
"       <td>",
"        <p>",
"         Lima, Peru",
"        </p>",
"        <p>",
"         Referral hospital",
"        </p>",
"        <p>",
"         n = 48",
"        </p>",
"        <p>",
"         All HIV negative",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Individualized based on DST",
"        </p>",
"        <p>",
"         Average 5.3 (+/- 1.3) TB meds",
"        </p>",
"        <p>",
"         Treatment duration: &ge;18 months and &ge;8 months with injectable drug",
"        </p>",
"        <p>",
"         Community management once medically stable",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         19 (40 percent) treatment failures",
"        </p>",
"        <p>",
"         11 (23 percent) died",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Keshavjee et al.",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"       <td>",
"        2000-2004",
"       </td>",
"       <td>",
"        <p>",
"         Tomsk Oblast, Russia",
"        </p>",
"        <p>",
"         Civilian and prison populations",
"        </p>",
"        <p>",
"         n = 29",
"        </p>",
"        <p>",
"         All HIV negative",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Individualized based on DST",
"        </p>",
"        <p>",
"         &ge;5 susceptible drugs",
"        </p>",
"        <p>",
"         Treatment duration: 18.2-23 months",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         15 (52 percent) treatment failures",
"        </p>",
"        <p>",
"         2 (7 percent) died",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gandhi et al.",
"        <sup>",
"         [5]",
"        </sup>",
"       </td>",
"       <td>",
"        2005-2006",
"       </td>",
"       <td>",
"        <p>",
"         Tugela Ferry, South Africa",
"        </p>",
"        <p>",
"         Rural district hospital",
"        </p>",
"        <p>",
"         n = 53",
"        </p>",
"        <p>",
"         44 (100 percent of those tested) were HIV positive",
"        </p>",
"       </td>",
"       <td>",
"        Not reported",
"       </td>",
"       <td>",
"        <p>",
"         52 (98 percent) died",
"        </p>",
"        <p>",
"         16 days median survival from time of culture diagnosis",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dheda et al.",
"        <sup>",
"         [6]",
"        </sup>",
"       </td>",
"       <td>",
"        2002-2008",
"       </td>",
"       <td>",
"        <p>",
"         South Africa",
"        </p>",
"        <p>",
"         4 provincial referral centers",
"        </p>",
"        <p>",
"         n = 174",
"        </p>",
"        <p>",
"         47 percent HIV-infected",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Individualized based on limited DST",
"        </p>",
"        <p>",
"         Backbone of capreomycin and PAS in most cases",
"        </p>",
"        <p>",
"         Moxifloxacin available in one center",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Mortality in 34/82 (41 percent) with HIV; 28/92 (30 percent) without HIV",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shenoi et al.",
"        <sup>",
"         [7]",
"        </sup>",
"       </td>",
"       <td>",
"        2005-2008",
"       </td>",
"       <td>",
"        <p>",
"         Tugela Ferry, South Africa",
"        </p>",
"        <p>",
"         Rural district hospital",
"        </p>",
"        <p>",
"         n = 142",
"        </p>",
"        <p>",
"         129 (91 percent) HIV-positive",
"        </p>",
"       </td>",
"       <td>",
"        Standardized intensive phase of ethambutol, pyrazinamide, ethionamide, cycloserine or terizidone, para-aminosalicylic acid, and capreomycin.",
"       </td>",
"       <td>",
"        <p>",
"         69 survivors; median survival 565 days [IQR 384-774]",
"        </p>",
"        <p>",
"         73 non-survivors; median survival 34 days [IQR 18-90]",
"        </p>",
"        <p>",
"         Survival associated with less advanced stages of TB and HIV at diagnosis, absence of multiorgan dysfunction and use of ART",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ART: antiretroviral therapy.",
"     <br>",
"      DST: drug susceptibility testing.",
"      <br>",
"       * XDR TB defined as resistance to isoniazid, rifampin, one or more fluoroquinolone and one or more injectable agent (amikacin, kanamycin, or capreomycin) in all studies except Shah et al. which also included resistance to any rifamycin (rifampin and rifabutin).",
"       <br>",
"        <font class=\"bullet\">",
"         &bull;",
"        </font>",
"        All studies are descriptive analyses except Keshavjee et al. which is a retrospective cohort study and Shenoi et al which is a case-control study.",
"        <br>",
"         &Delta; The 18 cases in Banerjee et al. are included in the 83 cases from Shah et al.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <ol>",
"      <li>",
"       Shah NS, Pratt R, Armstrong L, et al. Extensively Drug Resistant Tuberculosis in the United States, 1993-2007. JAMA 2008; 300(18):2153.",
"      </li>",
"      <li>",
"       Kim H, Hwang SS, Kim HJ, et al. Impact of Extensive Drug Resistance on Treatment Outcomes in Non-HIV infected Patients with Multidrug-Resistant Tuberculosis. Clinical Infectious Disease 2007; 45:1290.",
"      </li>",
"      <li>",
"       Mitnick CD, Shin SS, Seung KJ, et al. Comprehensive Treatment of Extensively Drug-Resistant Tuberculosis.&nbsp;N&nbsp;Engl J Med&nbsp;2008; 359:563.",
"      </li>",
"      <li>",
"       Keshavjee S, Gelmanova IY, Farmer PE, et al. Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study. Lancet 2008; 372:1363.",
"      </li>",
"      <li>",
"       Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368:1575.",
"      </li>",
"      <li>",
"       Dheda, K, Shean, K, Zumla, A, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet 2010; 375:1798.",
"      </li>",
"      <li>",
"       Shenoi SV, Brooks RP, Barbour R, et al. Survival from XDR-TB is associated with modifiable clinical characteristics in rural South Africa. PLoS One 2012; 7:e31786.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_44_7886=[""].join("\n");
var outline_f7_44_7886=null;
var title_f7_44_7887="ICS and bone mineral density";
var content_f7_44_7887=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F66311&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F66311&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 563px\">",
"   <div class=\"ttl\">",
"    Change in bone mineral density with inhaled glucocorticoids",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 543px; height: 399px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    For both the total hip and the trochanter, the rate of decline in bone density was 0.00044 g/cm",
"    <sup>",
"     2",
"    </sup>",
"    per year for each additional daily puff of inhaled glucocorticoid (P = 0.01 and P = 0.005, respectively). The solid line in each panel represents the mean yearly change in bone density. The dashed lines indicate the 95 percent confidence interval for the mean.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Isreal E, Banerjee TR, Fitzmaurice GM, et al. N Engl J Med 2001; 345:941.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_44_7887=[""].join("\n");
var outline_f7_44_7887=null;
